SMITH
ET AL., ACC/AHA GUIDELINES FOR PERCUTANEOUS CORONARY
INTERVENTION
(REVISION OF THE 1993 PTCA GUIDELINES)
JACC VOL. 37, NO. 8, JUNE 2001:2239i-lxvi
ACC/AHA
Guidelines for Percutaneous Coronary Intervention (Revision
of the 1993 PTCA Guidelines)
A
Report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines
(Committee to Revise the 1993 Guidelines for Percutaneous
Transluminal Coronary Angioplasty)
Endorsed
by the Society for Cardiac Angiography and Interventions
References
1.
Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-8.
2.
Kent KM, Bentivoglio LG, Block PC, et al. Percutaneous transluminal coronary angioplasty: report from the Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1982;49:2011-20.
3.
Williams DO, Riley RS, Singh AK, Most AS. Restoration of normal coronary hemodynamics and myocardial metabolism after percutaneous transluminal coronary angioplasty. Circulation 1980;62:653-6.
4.
Miller DD, Verani MS. Current status of myocardial perfusion imaging after percutaneous transluminal coronary angioplasty.J Am Coll Cardiol 1994;24:260-6.
5.
Detre KM, Holmes DR Jr, Holubkov R, et al. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990;82:739-50.
6.
Detre KM, Holubkov R, Kelsey S, et al. Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981: the National Heart, Lung, and Blood Institute Registry. N Engl J Med 1988;318:265-70.
7.
O'Keefe JHJr, Rutherford BD, McConahay DR, et.al. Multivessel coronary angioplasty from 1980 to 1989: procedural results and long-term outcome. J Am Coll Cardiol 1990;16:1097-1102.
8.
American Heart Association. 2001 Heart and Stroke Statistical Update. 2001; Dallas, Tx. American Heart Association.
9.
Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. [published erratum appears in N Engl J Med 1997; 336:147]. N Engl J Med 1996;335:217-25.
10.
Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet 1993;341:573-580.
11.
King SB, III, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery: Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994;331:1044-50.
12.
Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease: German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med 1994;331:1037-43.
13.
Rodriguez A, Boullon F, Perez-Balino N, et.al. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. J Am Coll Cardiol 1993;22:1060-7.
14.
Pocock SJ, Henderson RA, Riockards AF, et.al. Meta-analysis of randomized trials comparing coronary angioplasty with bypass surgery. Lancet 1995;346:1184-9.
15.
American College of Cardiology-National Cardiovascular
Data Registry Version 2.0. American College of Cardiology
Web site. Available at: http://www.acc.org/ncdr/cathlab.htm.
Accessed April 4, 2001. 2001.
16.
Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1993;22:2033-54.
17.
Detre KM, Wright E, Murphy ML, Takaro T. Observer agreement in evaluating coronary angiograms. Circulation 1975;52:979-86.
18.
Brown BG, Bolson EL, Dodge HT. Quantitative computer techniques for analyzing coronary arteriograms. Prog Cardiovasc Dis 1986;28:403-18.
19.
Abdelmeguid AE, Topol EJ. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Circulation 1996;94:3369-75.
20.
Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-51.
21.
Hirshfeld JW Jr., Ellis SG, Faxon DP, et al. ACC clinical competence statement: recommendations for the assessment and maintenance of proficiency in coronary interventional procedures. J Am Coll Cardiol 1998;31:722-43.
22.
Anderson JL. Diagnostic Catheterization and Percutaneous Transluminal Coronary Intervention: Clinical Data Standards. J Am Coll Cardiol 2001 (In Press).
23.
Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation 2000;102:2945-51.
24.
Jacobs AK, Kelsey SF, Yeh W, et al. Documentation of decline in morbidity in women undergoing coronary angioplasty: a report from the 1993-94 NHLBI Percutaneous Transluminal Coronary Angioplasty Registry. National Heart, Lung, and Blood Institute. Am J Cardiol 1997;80:979-84.
25.
Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992;85:916-27.
26.
Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996;94:629-35.
27.
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization: the EPILOG Investigators. N Engl J Med 1997;336:1689-96.
28.
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
29.
Ellis SG, Cowley MJ, Whitlow PL, et al. Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 versus 1991: improved in-hospital and 12- month results. Multivessel Angioplasty Prognosis Study (MAPS) Group. J Am Coll Cardiol 1995;25:1137-42.
30.
Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71.
31.
Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
32.
Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med 1994;331:489-95.
33.
Fishman NW, Kennard ED, Steenkiste AR, Popma JJ, Baim DS, Detre KM. New Approaches to Coronary Intervention (NACI) registry: history and methods. Am J Cardiol 1997;80:10K-8K.
34.
Baim DS, Cutlip DE, Sharma SK, et al. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Circulation 1998;97:322-31.
35.
Rankin JM, Spinelli JJ, Carere RG, et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med 1999;341:1957-65.
36.
Herrman J, von Birgelen C, Jeremias A, Schmermund A, Volbracht L, Sack S. Higher rate of myocardial microinfarction by coronary stenting and rotational atherectomy than by balloon angioplasty. Circulation 2000;100:I-456 (Abstract).
37.
King SB, Yeh W, Holubkov R, et al. Balloon angioplasty versus new device intervention: clinical outcomes. A comparison of the NHLBI PTCA and NACI registries. J Am Coll Cardiol 1998;31:558-66.
38.
Feit F, Brooks MM, Sopko G, et al. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators. Circulation 2000;101:2795-802.
39.
McGrath PD, Malenka DJ, Wennberg DE, et al. Changing outcomes in percutaneous coronary interventions: a study of 34,752 procedures in northern New England, 1990 to 1997. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 1999;34:674-80.
40.
Grassman ED, Johnson SA, Krone RJ. Predictors of success and major complications for primary percutaneous transluminal coronary angioplasty in acute myocardial infarction: an analysis of the 1990 to 1994 Society for Cardiac Angiography and Interventions registries. J Am Coll Cardiol 1997;30:201-8.
41.
Marks DS, Mensah GA, Kennard ED, Detre K, Holmes DRJ. Race, baseline characteristics, and clinical outcomes after coronary intervention: The New Approaches in Coronary Interventions (NACI) registry. Am Heart J 2000;140:162-9.
42.
Holmes DR Jr, Berger PB, Garratt KN, et al. Application of the New York State PTCA mortality model in patients undergoing stent implantation. Circulation 2000;102:517-22.
43.
Hannan EL, Racz M, Ryan TJ, et al. Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. JAMA 1997;277:892-98.
44.
Peterson ED, Lansky AJ, Anstrom KJ, et al. Evolving trends in interventional device use and outcomes: results from the National Cardiovascular Network Database. Am Heart J 2000;139:198-207.
45.
King SB, III. Ten-year completed follow-up of percutaneous transluminal coronary angioplasty: the early Zurich experience. J Am Coll Cardiol 1993;22:353-60.
46.
Holmes DR Jr, Kip KE, Kelsey SF, Detre KM, Rosen AD. Cause of death analysis in the NHLBI PTCA Registry: results and considerations for evaluating long-term survival after coronary interventions. J Am Coll Cardiol 1997;30:881-7.
47.
Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997;96:1761-69.
48.
Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999;99:633-40.
49.
Kelsey SF, James M, Holubkov AL, Holubkov R, Cowley MJ, Detre KM. Results of percutaneous transluminal coronary angioplasty in women: 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation 1993;87:720-7.
50.
Holmes DR Jr, Detre KM, Williams DO, et al. Long-term outcome of patients with depressed left ventricular function undergoing percutaneous transluminal coronary angioplasty: the NHLBI PTCA Registry. Circulation 1993;87:21-9.
51.
Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation 1991;84:1426-36.
52.
Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-9.
53.
Ellis SG, Roubin GS, Wilentz J, Douglas JSJ, King SB, III. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-82.
54.
Pepine CJ, Hirshfeld JW, MacDonald RG, et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty: M-HEART Group. Circulation 1990;81:1753-61.
55.
Serruys PW, Rutsch W, Heyndrickx GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade: a randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation 1991;84:1568-80.
56.
O'Keefe JH, Jr., McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol 1992;19:1597-1600.
57.
Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation 1992;86:100-10.
58.
Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease: the CAVEAT Study Group. N Engl J Med 1993;329:221-7.
59.
Adelman AG, Cohen EA, Kimball BP, et al. A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending coronary artery. N Engl J Med 1993;329:228-33.
60.
Serruys PW, Klein W, Tijssen JP, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty: a multicenter randomized double-blind placebo-controlled trial. Circulation 1993;88:1588-1601.
61.
Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty: results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994;90:908-14.
62.
Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90:2248-57.
63.
Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 1994;331:1331-7.
64.
Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996;132:23-9.
65.
Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337:365-72.
66.
Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) [published erratum appears in Lancet 1998;352:1478]. Lancet 1998;352:673-81.
67.
Tamai H, Katoh O, Suzuki S, et al. Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT). Am Heart J 1999;138:968-75.
68.
Holmes D, Fitzgerald P, Goldberg S, et al. The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial. Am Heart J 2000;139:23-31.
69.
Haudenschild CC. Pathobiology of restenosis after angioplasty. Am J Med. 1993;94:40S-44S.
70.
Currier JW, Haudenschild C, Faxon DP. Pathophysiology of restenosis: clinical implications. In: Ischinger T, Gohlke H, eds. Strategies in Primary and Secondary Prevention of Coronary Artery Disease. W. Zuckschwerdt Verlag; 1992;p. 181-192.
71.
Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996;94:35-43.
72.
Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol 1995;25:516-20.
73.
Kuntz RE, Baim DS. Defining coronary restenosis: newer clinical and angiographic paradigms. Circulation 1993;88:1310-23.
74.
Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993;21:15-25.
75.
Blackshear JL, O'Callaghan WG, Califf RM. Medical approaches to prevention of restenosis after coronary angioplasty. J Am Coll Cardiol 1987;9:834-48.
76.
Bresee SJ, Jacobs AK, Garber GR, et al. Prior restenosis predicts restenosis after coronary angioplasty of a new significant narrowing. Am J Cardiol 1991;68:1158-62.
77.
Hirshfeld JW Jr, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators. J Am Coll Cardiol 1991;18:647-56.
78.
Popma JJ, Heuser R, Suntharalingam M, et al. Late clinical and angiographic outcomes after use of 90/Sr/90Y beta radiation for the treatment of in-stent restenosis: Results from the Stents and Radiation Therapy (START) Trial. J Am Coll Cardiol 2000; Final Program:54 (Abstract).
79.
Leon MB, Moses JW, Lansky AJ, et al. Intracoronary gamma radiation for the prevention of recurrent in-stent restenosis: final results from the Gamma-1 trial. Circulation 1999;100:I-75 (Abstract).
80.
Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000;101:2165-71.
81.
Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697-1703.
82.
Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697-1703.
83.
King SB, III, Williams DO, Chougule P, et al. Endovascular beta-radiation to reduce restenosis after coronary balloon angioplasty: results of the beta energy restenosis trial (BERT). Circulation 1998;97:2025-30.
84.
Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. J Am Coll Cardiol 1996;27:255-61.
85.
Penn IM, Ricci DR, Almond DG, et al. Coronary artery stenting reduces restenosis: final results from the Trial of Angioplasty and Stents in Canada (TASC) I. Circulation 2000;92: (suppl I) I-279 (Abstract).
86.
Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffre PA. A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. N Engl J Med 1997;336:817-22.
87.
George CJ, Baim DS, Brinker JA, et al. One-year follow-up of the Stent Restenosis (STRESS I) Study. Am J Cardiol 1998;81:860-5.
88.
Rodriguez A, Ayala F, Bernardi V, et al. Optimal coronary balloon angioplasty with provisional stenting versus primary stent (OCBAS): immediate and long-term follow-up results. J Am Coll Cardiol 1998;32:1351-7.
89.
Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999;341:319-27.
90.
Betriu A, Masotti M, Serra A, et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol 1999;34:1498-506.
91.
Weaver WD, Reisman MA, Griffin JJ, et al. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. Lancet 2000;355:2199-203.
92.
Al Suwaidi J, Berger PB, Holmes DR Jr. Coronary artery stents. JAMA 2000; 284:1828-36.
93.
Ellis SG, Roubin GS, King SB, III, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988;77:372-79.
94.
Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990;82:1193-1202.
95.
Hartzler GO, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV. "High-risk" percutaneous transluminal coronary angioplasty. Am J Cardiol 1988;61:33G-7G.
96.
Gaul G, Hollman J, Simpfendorfer C, Franco I. Acute occlusion in multiple lesion coronary angioplasty: frequency and management. J Am Coll Cardiol 1989;13:283-8.
97.
Ellis SG, Roubin GS, King SB, III, et al. In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8,207 procedures. J Am Coll Cardiol 1988;11:211-6.
98.
Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1988;12:529-45.
99.
de Feyter PJ, van den Brand M, Laarman GJ, et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up [published erratum appears in Circulation 1991;84:446]. Circulation 1991;83:927-36.
100.
Myler RK, Shaw RE, Stertzer SH, et al. Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol 1992;19:1641-52.
101.
Kastrati A, Schomig A, Elezi S, et al. Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999;100:1285-90.
102.
Tan KH, Sulke N, Taub N, Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience. J Am Coll Cardiol 1995;25:855-65.
103.
Kimmel SE, Berlin JA, Strom BL, Laskey WK. Development and validation of simplified predictive index for major complications in contemporary percutaneous transluminal coronary angioplasty practice: the Registry Committee of the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1995;26:931-8.
104.
Taliercio CP, Vlietstra RE, Fisher LD, Burnett JC. Risks for renal dysfunction with cardiac angiography. Ann Intern Med 1986;104:501-4.
105.
Ellis SG, Myler RK, King SB III, et al. Causes and correlates of death after unsupported coronary angioplasty: implications for use of angioplasty and advanced support techniques in high-risk settings. Am J Cardiol 1991;68:1447-51.
106.
Block P, Peterson E, Krone R, et al. Identification of variables needed to risk adjust outcome of coronary interventions: evidence-based guidelines for efficient data collection. J Am Coll Cardiol 1998;32:275-82.
107.
Bergelson BA, Jacobs AK, Cupples LA, et al. Prediction of risk for hemodynamic compromise during percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;70:1540-5.
108.
Califf RM, Phillips HR3, Hindman MC, et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol 1985;5:1055-63.
109.
Holmes DR Jr, Holubkov R, Vlietstra RE, et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1988;12:1149-55.
110.
Sinclair IN, McCabe CH, Sipperly ME, Baim DS. Predictors, therapeutic options and long-term outcome of abrupt reclosure. Am J Cardiol 1988;61:61G-6G.
111.
Bell MR, Holmes DRJ, Berger PB, Garratt KN, Bailey KR, Gersh BJ. The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty. JAMA 1993;269:2091-5.
112.
Cowley MJ, Mullin SM, Kelsey SF, et al. Sex differences in early and long-term results of coronary angioplasty in the NHLBI PTCA Registry. Circulation 1985;71:90-7.
113.
McEniery PT, Hollman J, Knezinek V, et al. Comparative safety and efficacy of percutaneous transluminal coronary angioplasty in men and in women. Cathet Cardiovasc Diagn 1987;13:364-71.
114. Kahn JK, Rutherford BD, McConahay DR, et al. Comparison of procedural results and risks of coronary angioplasty in men and women for conditions other than acute myocardial infarction. Am J Cardiol 1992;69:1241-2.
115.
Davis KB, Chaitman B, Ryan T, Bittner V, Kennedy JW. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. Coronary Artery Surgery Study. J Am Coll Cardiol 1995;25:1000-9.
116.
Mendes LA, Davidoff R, Cupples LA, Ryan TJ, Jacobs AK. Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997;134:207-12.
117. Malenka DJ, O'Connor GT, Quinton H, et al. Differences in outcomes between women and men associated with percutaneous transluminal coronary angioplasty. A regional prospective study of 13,061 procedures. Northern New England Cardiovascular Disease Study Group. Circulation 1996;94:II99-104.
118. Kornowski R, Lansky AJ, Mintz GS, et al. Comparison of men versus women in cross-sectional area luminal narrowing, quantity of plaque, presence of calcium in plaque, and lumen location in coronary arteries by intravascular ultrasound in patients with stable angina pectoris. Am J Cardiol 1997;79:1601-5.
119. Greenberg MA, Mueller HS. Why the excess mortality in women after PTCA? Circulation 1993;87:1030-2.
120. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women as compared to men undergoing coronary revascularization: a report from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1998;98:1279-85.
121. Movsowitz HD, Emmi RP, Manginas A, et al. Directional coronary atherectomy in women compared with men. Clin Cardiol 1994;17:597-602.
122. Bell MR, Grill DE, Garratt KN, Berger PB, Gersh BJ, Holmes DR, Jr. Long-term outcome of women compared with men after successful coronary angioplasty. Circulation 1995;91:2876-81.
123. Weintraub WS, Wenger NK, Kosinski AS, et al. Percutaneous transluminal coronary angioplasty in women compared with men. J Am Coll Cardiol 1994;24:81-90.
124. Robertson T, Kennard ED, Mehta S, et al. Influence of gender on in-hospital clinical and angiographic outcomes and on one-year follow-up in the New Approaches to Coronary Intervention (NACI) registry. Am J Cardiol 1997;80:26K-39K.
125. Thompson RC, Holmes DR Jr, Gersh BJ, et al. Percutaneous transluminal coronary angioplasty in the elderly: early- and long-term results. J Am Coll Cardiol 1991;17:1245-50.
126. Taddei CFG, Weintraub WS, Douglas JS Jr, et al. Influence of age on outcome after percutaneous transluminal coronary angioplasty. Am J Cardiol 1999;84:245-51.
127. Tsai TP, Chaux A, Kass RM, et al. Aortocoronary bypass surgery in septuagenarians and octogenarians. J Cardiovasc Surg (Torino) 1989;30:364-8.
128. Holt GW, Sugrue DD, Bresnahan JF, et al. Results of percutaneous transluminal coronary angioplasty for unstable angina pectoris in patients 70 years of age and older. Am J Cardiol 1988;61:994-7.
129. Simpfendorfer C, Raymond R, Schraider J, et al. Early- and long-term results of pecutaneous transluminal coronary angioplasty in patients 70 years of age and older with angina pectoris. Am J Cardiol 1988;62:959-61.
130. Gaxiola E, Vlietsra R, Browne KF, et al. Is the outcome of coronary stenting worse in elderly patients? J Interven Cardiol 1998;11:37-40.
131. Terrin ML, Williams DO, Kleiman NS, et al.
Two- and three-year results of the Thrombolysis in Myocardial
Infarction (TIMI) Phase II clinical trial. J Am Coll Cardiol 1993;22:1763-72.
132. Aguirre FV, Younis LT, Chaitman
BR, et al. Early and 1-year clinical outcome of patients'
evolving non-Q-wave versus Q-wave myocardial infarction
after thrombolysis: results from the TIMI II Study. Circulation
1995;91:2541-48.
133. Marso SP, Lincoff AM, Ellis SG,
et al. Optimizing the percutaneous interventional outcomes
for patients with diabetes mellitus: results of the EPISTENT
(Evaluation of platelet IIb/IIIa inhibitor for stenting
trial) diabetic substudy. Circulation 1999;100:2477-84.
134. Dorros G, Lewin RF, Mathiak LM.
Coronary angioplasty in patients with prior coronary artery
bypass surgery: all prior coronary artery bypass surgery
patients and patients more than 5 years after coronary
bypass surgery. Cardiol Clin 1989;7:791-803.
135. Plokker HW, Meester BH, Serruys
PW. The Dutch experience in percutaneous transluminal
angioplasty of narrowed saphenous veins used for aortocoronary
arterial bypass. Am J Cardiol 1991;67:361-6.
136. Webb JG, Myler RK, Shaw RE, et
al. Coronary angioplasty after coronary bypass surgery:
initial results and late outcome in 422 patients. J Am Coll Cardiol 1990;16:812-20.
137. Mathew V, Clavell AL, Lennon RJ,
Grill DE, Holmes DR Jr. Percutaneous coronary interventions
in patients with prior coronary artery bypass graft surgery:
changes in patient characteristics and outcome during
two decades. Am J Med 2000;108:127.
138. Bhatt DL, Topol E. Percutaneous
coronary intervention for patients with prior bypass surgery:
therapy in evolution. Am J Med 2000;108:176.
139. Savage MP, Douglas JSJ, Fischman
DL, et al. Stent placement compared with balloon angioplasty
for obstructed coronary bypass grafts: Saphenous Vein
De Novo Trial Investigators. N Engl J Med 1997;337:740-7.
140. Holmes DR Jr, Topol EJ, Califf
RM, et al. A multicenter, randomized trial of coronary
angioplasty versus directional atherectomy for patients
with saphenous vein bypass graft lesions: CAVEAT-II Investigators.
Circulation 1995;91:1966-74.
141. Pomerantz RM, Kuntz RE, Carrozza
JP, et al. Acute and long-term outcome of narrowed saphenous
venous grafts treated by endoluminal stenting and directional
atherectomy. Am J Cardiol 1992;70:161-7.
142. Wong SC, Baim DS, Schatz RA, et
al. Immediate results and late outcomes after stent implantation
in saphenous vein graft lesions: the multicenter U.S.
Palmaz-Schatz stent experience. The Palmaz-Schatz Stent
Study Group. J Am Coll Cardiol 1995;26:704-12.
143. Brener SJ, Ellis SG, Apperson-Hansen
C, Leon MB, Topol EJ. Comparison of stenting and balloon
angioplasty for narrowings in aortocoronary saphenous
vein conduits in place for more than five years. Am J
Cardiol 1997;79:13-8.
144. Crowley ST, Bies RD, Morrison
DA. Percutaneous transluminal angioplasty of internal
mammary arteries in patients with rest angina. Cathet Cardiovasc Diagn 1996;38:256-62.
145. Lopez JJ, Ho KK, Stoler RC, et
al. Percutaneous treatment of protected and unprotected
left main coronary stenoses with new devices: immediate
angiographic results and intermediate-term follow-up.
J Am Coll Cardiol 1997;29:345-52.
146. Teirstein PS, Warth DC, Haq N,
et al. High speed rotational coronary atherectomy for
patients with diffuse coronary artery disease. J Am Coll Cardiol 1991;18:1694-1701.
147. Sharma SK, Dangas G, Mehran R,
et al. Risk factors for the development of slow flow during
rotational coronary atherectomy. Am J Cardiol 1997;80:219-22.
148. Dehmer GJ, Nichols TC, Bode AP,
et al. Assessment of platelet activation by coronary sinus
blood sampling during balloon angioplasty and directional
coronary atherectomy. Am J Cardiol 1997;80:871-7.
149. Koch KC, vom DJ, Kleinhans E,
et al. Influence of a platelet GPIIb/IIIa receptor antagonist
on myocardial hypoperfusion during rotational atherectomy
as assessed by myocardial Tc-99m sestamibi scintigraphy.
J Am Coll Cardiol 1999;33:998-1004.
150. Bhatt DL, Lincoff AM, Califf RM,
et al. The benefit of abciximab in percutaneous coronary
revascularization is not device-specific. Am J Cardiol
2000;85:1060-64.
151. Ellis SG, Ajluni S, Arnold AZ,
et al. Increased coronary perforation in the new device
era: incidence, classification, management, and outcome.
Circulation 1994;90:2725-30.
152. Ajluni SC, Glazier S, Blankenship
L, O'Neill WW, Safian RD. Perforations after percutaneous
coronary interventions: clinical, angiographic, and therapeutic
observations. Cathet Cardiovasc Diagn 1994;32:206-12.
153. Vogel RA, Tommaso CL, Gundry SR.
Initial experience with coronary angioplasty and aortic
valvuloplasty using elective semipercutaneous cardiopulmonary
support. Am J Cardiol 1988;62:811-3.
154. Shawl FA, Domanski MJ, Hernandez
TJ, Punja S. Emergency percutaneous cardiopulmonary bypass
support in cardiogenic shock from acute myocardial infarction.
Am J Cardiol 1989;64:967-70.
155. Anwar A, Mooney MR, Stertzer SH,
et al. Intra-aortic balloon counter pulsation support
for elective coronary angioplasty in the setting of poor
left ventricular function: a two center experience. J
Invas Cardiol 1990;2:175-80.
156. Kreidieh I, Davies DW, Lim R,
et al. High-risk coronary angioplasty with elective intra-aortic
balloon pump support. Int J Cardiol 1992;35:147-52.
157. Loop FD, Lytle BW, Cosgrove DM,
et al. Influence of the internal-mammary-artery graft
on 10-year survival and other cardiac events. N Engl J Med 1986;314:1-6.
158. Kshettry VR, Flavin TF, Emery
RW, Nicoloff DM, Arom KV, Petersen RJ. Does multivessel,
off-pump coronary artery bypass reduce postoperative morbidity?
Ann Thorac Surg 2000;69:1725-30.
159. Alderman EL, Bourassa MG, Cohen
LS, et al. Ten-year follow-up of survival and myocardial
infarction in the randomized Coronary Artery Surgery Study.
Circulation 1990;82:1629-46.
160. Eighteen-year follow-up in the
Veterans Affairs Cooperative Study of Coronary Artery
Bypass Surgery for stable angina: the VA Coronary Artery
Bypass Surgery Cooperative Study Group. Circulation 1992;86:121-30.
161. Danchin N, Brengard A, Ethevenot
G, et al. Ten year follow up of patients with single vessel
coronary artery disease that was suitable for percutaneous
transluminal coronary angioplasty. Br Heart J 1988;59:275-9.
162. Hueb WA, Bellotti G, de Oliveira
SA, et al. The Medicine, Angioplasty or Surgery Study
(MASS): a prospective, randomized trial of medical therapy,
balloon angioplasty or bypass surgery for single proximal
left anterior descending artery stenoses. J Am Coll Cardiol
1995;26:1600-5.
163. Goy JJ, Eeckhout E, Burnand B,
et al. Coronary angioplasty versus left internal mammary
artery grafting for isolated proximal left anterior descending
artery stenosis. Lancet 1994;343:1449-53.
164. Rodriguez A, Mele E, Peyregne
E, et al. Three-year follow-up of the Argentine Randomized
Trial of Percutaneous Transluminal Coronary Angioplasty
Versus Coronary Artery Bypass Surgery in Multivessel Disease
(ERACI). J Am Coll Cardiol 1996;27:1178-84.
165. Acute platelet inhibition with
abciximab does not reduce in-stent restenosis (ERASER
study). The ERASER Investigators. Circulation 1999;100:799-806.
166. Serruys PW, Unger F, van Hout
BA, et al. Comparison of Coronary Artery Bypass Surgery
and Stenting for the Treatment of Multivessel Disease.
N Engl J Med 2001 (In Press).
167. First-year results of CABRI (Coronary
Angioplasty versus Bypass Revascularisation Investigation):
CABRI Trial Participants. Lancet 1995;346:1179-84.
168. Carrie D, Elbaz M, Puel J, et
al. Five-year outcome after coronary angioplasty versus
bypass surgery in multivessel coronary artery disease:
results from the French Monocentric Study. Circulation
1997;96:II-1-6.
169. Weintraub WS, Stein B, Kosinski
A, et al. Outcome of coronary bypass surgery versus coronary
angioplasty in diabetic patients with multivessel coronary
artery disease. J Am Coll Cardiol 1998;31:10-9.
170. Rozenman Y, Sapoznikov D, Mosseri
M, et al. Long-term angiographic follow-up of coronary
balloon angioplasty in patients with diabetes mellitus:
a clue to the explanation of the results of the BARI study.
Balloon Angioplasty Revascularization Investigation. J Am Coll Cardiol 1997;30:1420-5.
171. Hlatky MA, Rogers WJ, Johnstone
I, et al. Medical care costs and quality of life after
randomization to coronary angioplasty or coronary bypass
surgery: Bypass Angioplasty Revascularization Investigation
(BARI) Investigators. N Engl J Med 1997;336:92-9.
172. Parisi AF, Folland ED, Hartigan
P. A comparison of angioplasty with medical therapy in
the treatment of single-vessel coronary artery disease.
Veterans Affairs ACME Investigators. N Engl J Med 1992;326:10-6.
173. Coronary angioplasty versus medical
therapy for angina: the second Randomised Intervention
Treatment of Angina (RITA-2) trial. RITA-2 trial participants.
Lancet 1997;350:461-8.
174. Pitt B, Waters D, Brown WV, et
al. Agressive lipid-lowering therapy compared with angioplasty
in stable coronary artery disease. Atorvastatin versus
Revascularization Treatment Investigators. N Engl J Med
1999;341:70-6.
175. Folland ED, Hartigan PM, Parisi
AF. Percutaneous transluminal coronary angioplasty versus
medical therapy for stable angina pectoris: outcomes for
patients with double-vessel versus single-vessel coronary
artery disease in a Veterans Affairs Cooperative randomized
trial. Veterans Affairs ACME Investigators. J Am Coll Cardiol 1997;29:1505-11.
176. Davies RF, Goldberg AD, Forman
S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study
two-year follow-up: outcomes of patients randomized to
initial strategies of medical therapy versus revascularization.
Circulation 1997;95:2037-43.
177. Dakik HA, Kleiman NS, Farmer JA,
et al. Intensive medical therapy versus coronary angioplasty
for suppression of myocardial ischemia in survivors of
acute myocardial infarction: a prospective, randomized
pilot study. Circulation 1998;98:2017-23.
178. Coronary artery surgery study
(CASS): a randomized trial of coronary artery bypass surgery:
quality of life in patients randomly assigned to treatment
groups. Circulation 1983;68:951-60.
179. Eleven-year survival in the Veterans
Administration randomized trial of coronary bypass surgery
for stable angina: the Veterans Administration Coronary
Artery Bypass Surgery Cooperative Study Group. N Engl J Med 1984;311:1333-9.
180. Shook TL, Sun GW, Burstein S,
Eisenhauer AC, Matthews RV. Comparison of percutaneous
transluminal coronary angioplasty outcome and hospital
costs for low-volume and high-volume operators. Am J Cardiol
1996;77:331-6.
181. Kimmel SE, Berlin JA, Laskey WK.
The relationship between coronary angioplasty procedure
volume and major complications. JAMA 1995;274:1137-42.
182. Jollis JG, Peterson ED, Nelson
CL, et al. Relationship between physician and hospital
coronary angioplasty volume and outcome in elderly patients.
Circulation 1997;95:2485-91.
183. Ellis SG, Weintraub W, Holmes
D, Shaw R, Block PC, King SB. Relation of operator volume
and experience to procedural outcome of percutaneous coronary
revascularization at hospitals with high interventional
volumes. Circulation 1997;95:2479-84.
184. Bashore TM, Bates ER, Berger PB,
et al. Catheterization laboratory standards: a report
of the American College of Cardiology Task Force on Clinical
Expert Consensus Documents (ACC/SCA&I Committee to
Develop an Expert Consensus Document on Catheterization
Laboratory Standards). J Am Coll Cardiol 2001 (In Press).
185. Pepine CJ, Babb JD, Brinker JA,
et al. Guidelines for training in adult cardiovascular
medicine. Core Cardiology Training Symposium (COCATS):
Task Force 3: training in cardiac catheterization and
interventional cardiology. J Am Coll Cardiol 1995;25:14-6.
186. Hirshfeld JW Jr, Banas JS Jr,
Brundage BH, et al. American College of Cardiology training
statement on recommendations for the structure of an optimal
adult interventional cardiology training program: a report
of the American College of Cardiology Task Force on Clinical
Expert Consensus Documents. J Am Coll Cardiol 1999;34:2141-7.
187. American Board of Internal Medicine:
Certification of Interventional Cardiology. 2000; Philadelphia
(PA): American Board of Internal Medicine.
188. Hamad N, Pichard AD, Lyle HR,
Lindsay J Jr. Results of percutaneous transluminal coronary
angioplasty by multiple, relatively low frequency operators:
1986-1987 experience. Am J Cardiol 1988;61:1229-31.
189. Teirstein PS. Credentialing for
coronary interventions: practice makes perfect. Circulation.
1997;95:2467-2470.
190. Hannan EL, Kilburn HJ, Bernard
H, O'Donnell JF, Lukacik G, Shields EP. Coronary artery
bypass surgery: the relationship between inhospital mortality
rate and surgical volume after controlling for clinical
risk factors. Med Care 1991;29:1094-1107.
191. Ryan TJ. The critical question
of procedure volume minimums for coronary angioplasty.
JAMA 1995;274:1169-70.
192. Kastrati A, Neumann FJ, Schomig
A. Operator volume and outcome of patients undergoing
coronary stent placement. J Am Coll Cardiol 1998;32:970-6.
193. Ryan TJ, Antman EM, Brooks NH,
et al. ACC/AHA guidelines for the management of patients
with acute myocardial infarction: a report of the American
College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee on Management
of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
194. Scanlon PJ, Faxon DP, Audet A,
et al. ACC/AHA guidelines for coronary angiography: a
report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee
on Coronary Angiography). J Am Coll Cardiol 1999;33:1756-1824.
195. Klinke WP, Hui W. Percutaneous
transluminal coronary angioplasty without on-site surgical
facilities. Am J Cardiol 1992;70:1520-5.
196. Meier B, Urban P, Dorsaz PA, Favre
J. Surgical standby for coronary balloon angioplasty.
JAMA 1992;268:741-5.
197. Iniguez A, Macaya C, Hernandez
R, et al. Comparison of results of percutaneous transluminal
coronary angioplasty with and without selective requirement
of surgical standby. Am J Cardiol 1992;69:1161-5.
198. Sowton E, de Bono D, Gribbin B,
O'Keeffe B, et al. Coronary angioplasty in the United
Kingdom. Br Heart J 1991;66:325-31.
199. Hubner PJ, Balcon R, Dyet J, Dymond
DS, et al. Surgical cover for percutaneous transluminal
coronary angioplasty. Br Heart J 1992;68:339-41.
200. Hasdai D, Berger PB, Bell MR,
Rihal CS, Garratt KN, Holmes DR Jr. The changing face
of coronary interventional practice: the Mayo Clinic experience.
Arch Intern Med 1997;157:677-82.
201. Altmann DB, Racz M, Battleman
DS, et al. Reduction in angioplasty complications after
the introduction of coronary stents: results from a consecutive
series of 2242 patients. Am Heart J 1996;132:503-7.
202. Stauffer JC, Eeckhout E, Vogt
P, Kappenberger L, Goy JJ. Stand-by versus stent-by during
percutaneous transluminal coronary angioplasty. Am Heart J 1995;130:21-6.
203. Berger PB, Stensrud PE, Daly RC,
et al. Time to reperfusion and other procedural characteristics
of emergency coronary artery bypass surgery after unsuccessful
coronary angioplasty. Am J Cardiol 1995;76:565-9.
204. Beyersdorf F, Mitrev Z, Sarai
K, et al. Changing patterns of patients undergoing emergency
surgical revascularization for acute coronary occlusion:
importance of myocardial protection techniques. J Thorac
Cardiovasc Surg 1993;106:137-48.
205. Nollert G, Amend J, Detter C,
Reichart B. Coronary artery bypass grafting after failed
coronary angioplasty: risk factors and long-term results.
Thorac Cardiovasc Surg 1995;43:35-9.
206. Lazar HL, Faxon DP, Paone G, et
al. Changing profiles of failed coronary angioplasty patients:
impact on surgical results. Ann Thorac Surg 1992;53:269-73.
207. Talley JD, Weintraub WS, Roubin
GS, et al. Failed elective percutaneous transluminal coronary
angioplasty requiring coronary artery bypass surgery:
in-hospital and late clinical outcome at 5 years. Circulation
1990;82:1203-13.
208. Eagle KA, Guyton RA, Davidoff
R, et al. Guidelines for coronary artery bypass graft
surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee
on Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol
1999;34:1262-1347.
209. Effectiveness of intravenous thrombolytic
treatment in acute myocardial infarction: Gruppo Italiano
per lo Studio della Streptochinasi nell'Infarto Miocardico
(GISSI). Lancet 1986;1:397-402.
210. Randomised trial of intravenous
streptokinase, oral aspirin, both, or neither among 17,187
cases of suspected acute myocardial infarction: ISIS-2.
ISIS-2 (Second International Study of Infarct Survival)
Collaborative Group. Lancet 1988;2:349-60.
211. Weaver WD, Cerqueira M, Hallstrom
AP, et al. Prehospital-initiated vs hospital-initiated
thrombolytic therapy: the Myocardial Infarction Triage
and Intervention Trial. JAMA 1993;270:1211-6.
212. Stone GW, Brodie BR, Griffin JJ,
et al. Role of cardiac surgery in the hospital phase management
of patients treated with primary angioplasty for acute
myocardial infarction. Am J Cardiol 2000;85:1292-6.
213. Vogel JH. Changing trends for
surgical standby in patients undergoing percutaneous transluminal
coronary angioplasty. Am J Cardiol 1992;69:25F-32F.
214. Wharton TP Jr, McNamara NS, Fedele
FA, Jacobs MI, Gladstone AR, Funk EJ. Primary angioplasty
for the treatment of acute myocardial infarction: experience
at two community hospitals without cardiac surgery. J Am Coll Cardiol 1999;33:1257-65.
215. Weaver WD, Litwin PE, Martin JS.
Use of direct angioplasty for treatment of patients with
acute myocardial infarction in hospitals with and without
on-site cardiac surgery: the Myocardial Infarction, Triage,
and Intervention Project Investigators. Circulation 1993;88:2067-75.
216. Iannone LA, Anderson SM, Phillips
SJ. Coronary angioplasty for acute myocardial infarction
in a hospital without cardiac surgery. Tex Heart Inst
J 1993;20:99-104.
217. Brush JEJ, Thompson S, Ciuffo
AA, et al. Retrospective comparison of a strategy of primary
coronary angioplasty versus intravenous thrombolytic therapy
for acute myocardial infarction in a community hospital
without cardiac surgical backup. J Invasive Cardiol 1996;8:91-8.
218. Smyth DW, Richards AM, Elliott
JM. Direct angioplasty for myocardial infarction: one-year
experience in a center with surgical backup 220 miles
away. J Invasive Cardiol 1997;9:324-32.
219. Weaver WD, Parsons LS, Every NR.
Primary coronary angioplasty in hospitals with and without
surgery backup. J Invas Cardiol 1995;7:34F-9F.
220. Meier B. Surgical standby for
percutaneous transluminal coronary angioplasty. In: Topol
EJ, ed. Textbook of Interventional Cardiology. 3rd ed.
Phildelphia: W.B. Saunders Company; 1999;p. 466-74.
221. Moosvi AR, Khaja F, Villanueva
L, Gheorghiade M, Douthat L, Goldstein S. Early revascularization
improves survival in cardiogenic shock complicating acute
myocardial infarction. J Am Coll Cardiol 1992;19:907-14.
222. Hochman JS, Sleeper LA, Webb JG,
et al. Early revascularization in acute myocardial infarction
complicated by cardiogenic shock. SHOCK Investigators.
Should We Emergently Revascularize Occluded Coronaries
for Cardiogenic Shock. N Engl J Med 1999;341:625-34.
223. Vogel JH. Angioplasty in the patient
with an evolving myocardial infarction: with and without
surgical backup. Clin Cardiol 1992;15:880-2.
224. Lange RA, Hillis LD. Should thrombolysis
or primary angioplasty be the treatment of choice for
acute myocardial infarction? Thrombolysis: the preferred
treatment. N Engl J Med 1996;335:1311-2; discussion 1316-7.
225. Antman EM, Giugliano RP, Gibson
CM, et al. Abciximab facilitates the rate and extent of
thrombolysis: results of the thrombolysis in myocardial
infarction (TIMI) 14 trial. The TIMI 14 Investigators.
Circulation 1999;99:2720-32.
226. Magid DJ, Calonge BN, Rumsfeld
JS, et al. Relation between hospital primary angioplasty
volume and mortality for patients with acute MI treated
with primary angioplasty vs thrombolytic therapy. JAMA
2000;284:3131-8.
227. McGrath PD, Wennberg DE, Dickens
JD, et al. Relation between operator and hospital volume
and outcomes following percutaneous coronary interventions
in the era of the coronary stent. JAMA 2000;284:3139-44.
228. Canto JG, Every NR, Magid DJ,
et al. The volume of primary angioplasty procedures and
survival after acute myocardial infarction: National Registry
of Myocardial Infarction 2 Investigators. N Engl J Med
2000;342:1573-80.
229. Cannon CP, Gibson CM, Lambrew
CT, et al. Relationship of symptom-onset-to-balloon time
and door-to-balloon time with mortality in patients undergoing
angioplasty for acute myocardial infarction. JAMA 2000;283:2941-7.
230. Caputo RP, Ho KK, Stoler RC, et
al. Effect of continuous quality improvement analysis
on the delivery of primary percutaneous transluminal coronary
angioplasty for acute myocardial infarction. Am J Cardiol
1997;79:1159-64.
231. Loubeyre C, Morice MC, Berzin
B, et al. Emergency coronary artery bypass surgery following
coronary angioplasty and stenting: results of a French
multicenter registry. Catheter Cardiovasc Interv 1999;47:441-8.
232. Vogt A, Bonzel T, Harmjanz D,
et al. PTCA registry of German community hospitals. Arbeitsgemeinschaft
Leitender Kardiologischer Krankenhausarzte (ALKK) Study
Group. Eur Heart J 1997;18:1110-4.
233. Dellavalle A, Steffenino G, Ribichini
F, Russo P, Uslenghi E. Elective coronary angioplasty
with and without surgical standby: clinical and angiographic
criteria for the selection of patients. Coron Artery Dis
1995;6:513-20.
234. Richardson SG, Morton P, Murtagh
JG, O'Keeffe DB, Murphy P, Scott ME. Management of acute
coronary occlusion during percutaneous transluminal coronary
angioplasty: experience of complications in a hospital
without on site facilities for cardiac surgery. BMJ 1990;300:355-8.
235. Reifart N, Preusler W, Schwarz
F, et al. A large center experience of coronary angioplasty
without on-site surgical standby. In: Topol EJ, Serruys
PW, eds. Current Review of Interventional Cardiology.
2nd ed. Philadelphia: Current Medicine; 1995;p. 296-303.
236. Yusuf S, Wittes J, Probstfield
J, Tyroler HA. Analysis and interpretation of treatment
effects in subgroups of patients in randomized clinical
trials. JAMA 1991;266:93-8.
237. Loop FD, Whitlow PL. "Beauty
is in the eye ...". Am J Cardiol 1992;70:1608-9.
238. Kent KM. Interventional cardiology:
1990s. Am J Cardiol 1992;70:1607-8.
239. Grines CL, Balestrini C, Westerhausen
DR, et al. A randomized trial of thrombolysis vs transfer
for primary PTCA in high risk AMI patients: results of
the AIR PAMI trial. J Am Coll Cardiol 2000;35:376A (Abstract).
240. Varnauskas E. Survival, myocardial
infarction, and employment status in a prospective randomized
study of coronary bypass surgery. Circulation 1985;72:V90-101.
241. Yusuf S, Zucker D, Peduzzi P,
et al. Effect of coronary artery bypass graft surgery
on survival: overview of 10-year results from randomised
trials by the Coronary Artery Bypass Graft Surgery Trialists
Collaboration [published erratum appears in Lancet 1994;344:1446].
Lancet 1994;344:563-70.
242. Braunwald E, Jones RH, Mark DB,
et al. Diagnosing and managing unstable angina. Agency
for Health Care Policy and Research. Circulation 1994;90:613-22.
243. Effects of tissue plasminogen
activator and a comparison of early invasive and conservative
strategies in unstable angina and non-Q-wave myocardial
infarction: results of the TIMI IIIB Trial. Thrombolysis
in Myocardial Ischemia. Circulation 1994;89:1545-56.
244. Williams DO, Braunwald E, Thompson
B, Sharaf BL, Buller CE, Knatterud GL. Results of percutaneous
transluminal coronary angioplasty in unstable angina and
non-Q-wave myocardial infarction: observations from the
TIMI IIIB Trial. Circulation 1996;94:2749-55.
245. Anderson HV, Cannon CP, Stone
PH, et al. One-year results of the Thrombolysis in Myocardial
Infarction (TIMI) IIIB clinical trial. A randomized comparison
of tissue-type plasminogen activator versus placebo and
early invasive versus early conservative strategies in
unstable angina and non-Q wave myocardial infarction.
J Am Coll Cardiol 1995;26:1643-50.
246. Boden WE, O'Rourke RA, Crawford
MH, et al. Outcomes in patients with acute non-Q-wave
myocardial infarction randomly assigned to an invasive
as compared with a conservative management strategy. Veterans
Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH)
Trial Investigators [published erratum appears in N Engl J Med 1998;339:1091]. N Engl J Med 1998;338:1785-92.
247. Invasive compared with non-invasive
treatment in unstable coronary-artery disease: FRISC II
prospective randomised multicentre study. FRagmin and
Fast Revascularisation during InStability in Coronary
artery disease Investigators. Lancet 1999;354:708-15.
248. Long-term low-molecular-mass heparin
in unstable coronary-artery disease: FRISC II prospective
randomised multicentre study. FRagmin and Fast Revascularisation
during InStability in Coronary artery disease. Investigators.
Lancet 1999;354:701-7.
249. Cannon C. TACTICS (Treat Angina
with Aggrastat + Determine Cost of Therapy with an Invasive
or Conservative Strategy)--TIMI 18. Clin Cardiol 2001;24:86
(Abstract).
250. Braunwald E, Antman EM, Beasley
JW, et al. ACC/AHA guidelines for the management of patients
with unstable angina and non-ST-segment elevation myocardial
infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee
on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36:970-1062.
251. Every NR, Parsons LS, Hlatky M,
Martin JS, Weaver WD. A comparison of thrombolytic therapy
with primary coronary angioplasty for acute myocardial
infarction. Myocardial Infarction Triage and Intervention
Investigators. N Engl J Med 1996;335:1253-60.
252. A prospective trial of intravenous
streptokinase in acute myocardial infarction (I.S.A.M.):
mortality, morbidity, and infarct size at 21 days. The
I.S.A.M. Study Group. N Engl J Med 1986;314:1465-71.
253. Effect of intravenous APSAC on
mortality after acute myocardial infarction: preliminary
report of a placebo-controlled clinical trial. AIMS Trial
Study Group. Lancet 1988;1:545-9.
254. An international randomized trial
comparing four thrombolytic strategies for acute myocardial
infarction: the GUSTO investigators. N Engl J Med 1993;329:673-82.
255. Indications for fibrinolytic therapy
in suspected acute myocardial infarction: collaborative
overview of early mortality and major morbidity results
from all randomised trials of more than 1000 patients.
Fibrinolytic Therapy Trialists' (FTT) Collaborative Group
[published erratum appears in Lancet 1994;343:742]. Lancet
1994;343:311-22.
256. Wilcox RG, von der Lippe G, Olsson
CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen
activator for mortality reduction in acute myocardial
infarction. Anglo-Scandinavian Study of Early Thrombolysis
(ASSET). Lancet 1988;2:525-30.
257. O'Neill WW, Brodie BR, Ivanhoe
R, et al. Primary coronary angioplasty for acute myocardial
infarction (the Primary Angioplasty Registry). Am J Cardiol
1994;73:627-34.
258. O'Keefe JH, Jr., Bailey WL, Rutherford
BD, et al. Primary angioplasty for acute myocardial infarction
in 1,000 consecutive patients. Results in an unselected
poputaion and high-risk groups. Am J Cardiol 1993;72:107G-15G.
259. Laster SB, O'Keefe JH, Jr., Gibbons
RJ. Incidence and importance of thrombolysis in myocardial
infarction grade 3 flow after primary percutaneous transluminal
coronary angioplasty for acute myocardial infarction.
Am J Cardiol 1996;78:623-26.
260. Brodie BR, Grines CL, Ivanhoe
R, et al. Six-month clinical and angiographic follow-up
after direct angioplasty for acute myocardial infarction:
final results from the Primary Angioplasty Registry. Circulation
1994;90:156-62.
261. Brodie BR, Weintraub RA, Stuckey
TD, et al. Outcomes of direct coronary angioplasty for
acute myocardial infarction in candidates and non-candidates
for thrombolytic therapy. Am J Cardiol 1991;67:7-12.
262. Stone GW, Brodie BR, Griffin JJ,
et al. Prospective, multicenter study of the safety and
feasibility of primary stenting in acute myocardial infarction:in-hospital
and 30-day results of the PAMI stent pilot trial. Primary
Angioplasty in Myocardial Infarction Stent Pilot Trial
Investigators. J Am Coll Cardiol 1998;31:23-30.
263. Grines CL, Marsalese DL, Brodie
B, et al. Safety and cost-effectiveness of early discharge
after primary angioplasty in low-risk patients with acute
myocardial infarction. PAM-II Investigators. Primary Angioplasty
in Myocardial Infarction. J Am Coll Cardiol 1998;31:967-72.
264. Grines CL, Cox DA, Stone GW, et
al. Coronary angioplasty with or without stent implantation
for acute myocardial infarction. Stent Primary Angioplasty
in Myocardial Infarction Study Group. N Engl J Med 1999;341:1949-56.
265. Cox DA, Stone GW, Brodie B, et
al. Stent PAMI: Are Excellent Outcomes Acheived Only by
Experienced Sites? J Am Coll Cardiol 2000;35:(suppl A)
363A (Abstract).
266. Grines CL, Browne KF, Marco J,
et al. A comparison of immediate angioplasty with thrombolytic
therapy for acute myocardial infarction. The Primary Angioplasty
in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-79.
267. Zijlstra F, de Boer MJ, Hoorntje
JC, Reiffers S, Reiber JH, Suryapranata H. A comparison
of immediate coronary angioplasty with intravenous streptokinase
in acute myocardial infarction. N Engl J Med 1993;328:680-4.
268. Gibbons RJ, Holmes DR, Reeder
GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty
compared with the administration of a thrombolytic agent
followed by conservative treatment for myocardial infarction.
The Mayo Coronary Care Unit and Catheterization Laboratory
Groups. N Engl J Med 1993;328:685-91.
269. Blankenship JC, Mishkel GJ, Chambers
CE, et al. Ad hoc coronary intervention. Cathet Cardiovasc
Intervent 2000;49:130-4.
270. A clinical trial comparing primary
coronary angioplasty with tissue plasminogen activator
for acute myocardial infarction. The Global Use of Strategies
to Open Occluded Coronary Arteries in Acute Coronary Syndromes
(GUSTO IIb) Angioplasty Substudy Investigators [published
erratum appears in N Engl J Med 1997;337:287]. N Engl J Med 1997;336:1621-8.
271. Michels KB, Yusuf S. Does PTCA
in acute myocardial infarction affect mortality and reinfarction
rates? A quantitative overview (meta-analysis) of the
randomized clinical trials. Circulation 1995;91:476-85.
272. Weaver WD, Simes RJ, Betriu A,
et al. Comparison of primary coronary angioplasty and
intravenous thrombolytic therapy for acute myocardial
infarction: a quantitative review. JAMA 1997;278:2093-8.
273. Rodriguez A, Bernardi V, Fernandez
M, et al. In-hospital and late results of coronary stents
versus conventional balloon angioplasty in acute myocardial
infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial
Infarction. Am J Cardiol 1998;81:1286-91.
274. Antoniucci D, Santoro GM, Bolognese
L, Valenti R, Trapani M, Fazzini PF. A clinical trial
comparing primary stenting of the infarct-related artery
with optimal primary angioplasty for acute myocardial
infarction: results from the Florence Randomized Elective
Stenting in Acute Coronary Occlusions (FRESCO) trial.
J Am Coll Cardiol 1998;31:1234-39.
275. Maillard L, Hamon M, Khalife K,
et al. A comparison of systematic stenting and conventional
balloon angioplasty during primary percutaneous transluminal
coronary angioplasty for acute myocardial infarction.
STENTIM-2 Investigators. J Am Coll Cardiol 2000;35:1729-36.
276. Suryapranata H, van't Hof AW,
Hoorntje JC, de Boer MJ, Zijlstra F. Randomized comparison
of coronary stenting with balloon angioplasty in selected
patients with acute myocardial infarction. Circulation
1998;97:2502-5.
277. Saito S, Hosokawa G, Tanaka S,
Nakamura S. Primary stent implantation is superior to
balloon angioplasty in acute myocardial infarction: final
results of the primary angioplasty versus stent implantation
in acute myocardial infarction (PASTA) trial. PASTA Trial
Investigators. Catheter Cardiovasc Interv 1999;48:262-8.
278. Scheller B, Hennen B, Severin-Kneib
S, et al. Long-term follow-up of a randomized study of
primary stenting versus angioplasty in acute myocardial
infarction. Am J Med 2001;110:1-6.
279. Barbash GI, Roth A, Hod H, et
al. Randomized controlled trial of late in-hospital angiography
and angioplasty versus conservative management after treatment
with recombinant tissue-type plasminogen activator in
acute myocardial infarction. Am J Cardiol 1990;66:538-45.
280. SWIFT trial of delayed elective
intervention v conservative treatment after thrombolysis
with anistreplase in acute myocardial infarction: SWIFT
(Should We Intervene Following Thrombolysis?) Trial Study
Group. BMJ 1991;302:555-60.
281. Comparison of invasive and conservative
strategies after treatment with intravenous tissue plasminogen
activator in acute myocardial infarction: results of the
thrombolysis in myocardial infarction (TIMI) phase II
trial. The TIMI Study Group. N Engl J Med 1989;320:618-27.
282. Duber C, Jungbluth A, Rumpelt
HJ, Erbel R, Meyer J, Thoenes W. Morphology of the coronary
arteries after combined thrombolysis and percutaneous
transluminal coronary angioplasty for acute myocardial
infarction. Am J Cardiol 1986;58:698-703.
283. Rogers WJ, Bowlby LJ, Chandra
NC, et al. Treatment of myocardial infarction in the United
States (1990 to 1993): observations from the National
Registry of Myocardial Infarction. Circulation 1994;90:2103-14.
284. Ellis SG, Debowey D, Bates ER,
Topol EJ. Treatment of recurrent ischemia after thrombolysis
and successful reperfusion for acute myocardial infarction:
effect on in-hospital mortality and left ventricular function.
J Am Coll Cardiol 1991;17:752-7.
285. Rogers WJ, Baim DS, Gore JM, et
al. Comparison of immediate invasive, delayed invasive,
and conservative strategies after tissue-type plasminogen
activator. Results of the Thrombolysis in Myocardial Infarction
(TIMI) Phase II-A trial. Circulation 1990;81:1457-76.
286. Muller DW, Topol EJ, Ellis SG,
et al. Determinants of the need for early acute intervention
in patients treated conservatively after thrombolytic
therapy for acute myocardial infarction: TAMI-5 Study
Group. J Am Coll Cardiol 1991;18:1594-1601.
287. Trial of abciximab with and without
low-dose reteplase for acute myocardial infarction. Strategies
for Patency Enhancement in the Emergency Department (SPEED)
Group. Circulation 2000;101:2788-94.
288. Califf RM. Glycoprotein IIb/IIIa
blockade and thrombolytics: early lessons from the SPEED
and GUSTO IV trials. Am Heart J 1999;138:S12-S5
289. Califf RM, Woodlief LH, Harrell
FEJ, et al. Selection of thrombolytic therapy for individual
patients: development of a clinical model. GUSTO-I Investigators.
Am Heart J 1997;133:630-9.
290. Ross AM, Lundergan CF, Rohrbeck
SC, et al. Rescue angioplasty after failed thrombolysis:
technical and clinical outcomes in a large thrombolysis
trial. GUSTO-1 Angiographic Investigators. Global Utilization
of Streptokinase and Tissue Plasminogen Activator for
Occluded Coronary Arteries. J Am Coll Cardiol 1998;31:1511-7.
291. Ellis SG, da Silva ER, Spaulding
CM, Nobuyoshi M, Weiner B, Talley JD. Review of immediate
angioplasty after fibrinolytic therapy for acute myocardial
infarction: insights from the RESCUE I, RESCUE II, and
other contemporary clinical experiences. Am Heart J 2000;139:1046-53.
292. Ellis SG, da Silva ER, Heyndrickx
G, et al. Randomized comparison of rescue angioplasty
with conservative management of patients with early failure
of thrombolysis for acute anterior myocardial infarction.
Circulation 1994;90:2280-84.
293. Hochman JS, Boland J, Sleeper
LA, et al. Current spectrum of cardiogenic shock and effect
of early revascularization on mortality. Results of an
International Registry. SHOCK Registry Investigators.
Circulation 1995;91:873-81.
294. Williams DO, Braunwald E, Knatterud
G, et al. One-year results of the Thrombolysis in Myocardial
Infarction investigation (TIMI) Phase II Trial. Circulation
1992;85:533-42.
295. Ross AM, Coyne KS, Reiner JS,
et al. A randomized trial comparing primary angioplasty
with a strategy of short-acting thrombolysis and immediate
planned rescue angioplasty in acute myocardial infarction:
the PACT trial. PACT investigators. Plasminogen-activator
Angioplasty Compatibility Trial. J Am Coll Cardiol 1999;34:1954-62.
296. Jeremy RW, Hackworthy RA, Bautovich
G, Hutton BF, Harris PJ. Infarct artery perfusion and
changes in left ventricular volume in the month after
acute myocardial infarction. J Am Coll Cardiol 1987;9:989-95.
297. Kersschot IE, Brugada P, Ramentol
M, et al. Effects of early reperfusion in acute myocardial
infarction on arrhythmias induced by programmed stimulation:
a prospective, randomized study. J Am Coll Cardiol 1986;7:1234-42.
298. Stadius ML, Davis K, Maynard C,
Ritchie JL, Kennedy JW. Risk stratification for 1 year
survival based on characteristics identified in the early
hours of acute myocardial infarction: the Western Washington
Intracoronary Streptokinase Trial. Circulation 1986;74:703-11.
299. Topol EJ, Califf RM, Vandormael
M, et al. A randomized trial of late reperfusion therapy
for acute myocardial infarction: Thrombolysis and Angioplasty
in Myocardial Infarction-6 Study Group. Circulation 1992;85:2090-9.
300. Dzavik V, Beanlands DS, Davies
RF, et al. Effects of late percutaneous transluminal coronary
angioplasty of an occluded infarct-related coronary artery
on left ventricular function in patients with a recent
(< 6 weeks) Q-wave acute myocardial infarction (Total
Occlusion Post-Myocardial Infarction Intervention Study
[TOMIIS]-a pilot study). Am J Cardiol 1994;73:856-61.
301. Cigarroa RG, Lange RA, Hillis
LD. Prognosis after acute myocardial infarction in patients
with and without residual anterograde coronary blood flow.
Am J Cardiol 1989;64:155-60.
302. Kim CB, Braunwald E. Potential
benefits of later reperfusion of infarcted myocardium.
The open artery hypothesis. Circulation 1993;88:2426-36.
303. Fortin DF, Califf RM. Long-term
survival from acute myocardial infarction: salutary effect
of an open coronary vessel. Am J Med 1990;88:9N-15N.
304. Lamas GA, Pfeffer MA, Braunwald
E. Patency of the infarct-related coronary artery and
ventricular geometry. Am J Cardiol 1991;68:41D-51D.
305. Pizzetti G, Belotti G, Margonato
A, et al. Coronary recanalization by elective angioplasty
prevents ventricular dilation after anterior myocardial
infarction. J Am Coll Cardiol 1996;28:837-45.
306. Boehrer JD, Glamann DB, Lange
RA, et al. Effect of coronary angioplasty on late potentials
one to two weeks after acute myocardial infarction. Am
J Cardiol 1992;70:1515-19.
307. McCully RB, elZeky F, vanderZwaag
R, et al. Impact of patency of the left anterior descending
coronary artery on long-term survival. Am J Cardiol 1995;76:250-4.
308. Welty FK, Mittleman MA, Lewis
SM, et al. A patient infarct-related artery is associated
with reduced long-term mortality after percutaneous transluminal
coronary angioplasty for postinfarction ischemia and an
ejection fraction <50%. Circulation. 1996;93:1496-1501.
309. Nicod P, Gilpin EA, Dittrich H,
et al. Trends in use of coronary angiography in subacute
phase of myocardial infarction. Circulation 1991;84:1004-15.
310. Aguirre FV, McMahon RP, Mueller
H, et al. Impact of age on clinical outcome and postlytic
management strategies in patients treated with intravenous
thrombolytic therapy: results from the TIMI II Study.
TIMI II Investigators. Circulation 1994;90:78-86.
311. Schulman SP, Achuff SC, Griffith
LS, et al. Prognostic cardiac catheterization variables
in survivors of acute myocardial infarction: a five year
prospective study. J Am Coll Cardiol 1988;11:1164-72.
312. Mueller HS, Cohen LS, Braunwald
E, et al. Predictors of early morbidity and mortality
after thrombolytic therapy of acute myocardial infarction:
analyses of patient subgroups in the Thrombolysis in Myocardial
Infarction (TIMI) trial, phase II. Circulation 1992;85:1254-64.
313. Campeau L, Lesperance J, Hermann
J, Corbara F, Grondin CM, Bourassa MG. Loss of the improvement
of angina between 1 and 7 years after aortocoronary bypass
surgery: correlations with changes in vein grafts and
in coronary arteries. Circulation 1979;60:1-5.
314. Cameron A, Kemp HGJ, Shimomura
S, et al. Aortocoronary bypass surgery: a 7-year follow-up.
Circulation 1979;60:9-13.
315. Johnson WD, Kayser KL, Pedraza
PM. Angina pectoris and coronary bypass surgery: patterns
of prevalence and recurrence in 3105 consecutive patients
followed up to 11 years. Am Heart J 1984;108:1190-7.
316. Cameron A, Davis KB, Rogers WJ.
Recurrence of angina after coronary artery bypass surgery:
predictors and prognosis (CASS Registry). Coronary Artery
Surgery Study. J Am Coll Cardiol 1995;26:895-9.
317. Frick MH, Valle M, Harjola PT.
Progression of coronary artery disease in randomized medical
and surgical patients over a 5-year angiographic follow-up.
Am J Cardiol 1983;52:681-5.
318. Palac RT, Hwang MH, Meadows WR,
et al. Progression of coronary artery disease in medically
and surgically treated patients 5 years after randomization.
Circulation 1981;64:II17-21.
319. Lawrie GM, Lie JT, Morris GCJ,
Beazley HL. Vein graft patency and intimal proliferation
after aortocoronary bypass: early and long-term angiopathologic
correlations. Am J Cardiol 1976;38:856-62.
320. Goldman SL, Copeland J, Moritz
T, et al. Starting aspirin therapy after operation: effects
on early graft patency. Department of Veterans Affairs
Cooperative Study Group. Circulation 1991;84:520-6.
321. FitzGibbon GM, Burton JR, Leach
AJ. Coronary bypass graft fate: angiographic grading of
1400 consecutive grafts early after operation and of 1132
after one year. Circulation 1978;57:1070-4.
322. Hamby RI, Aintablian A, Handler
M, et al. Aortocoronary saphenous vein bypass grafts:
long-term patency, morphology and blood flow in patients
with patent grafts early after surgery. Circulation 1979;60:901-9.
323. Bourassa MG, Enjalbert M, Campeau
L, Lesperance J. Progression of atherosclerosis in coronary
arteries and bypass grafts: ten years later. Am J Cardiol
1984;53:102C-7C.
324. Bourassa MG, Fisher LD, Campeau
L, Gillespie MJ, McConney M, Lesperance J. Long-term fate
of bypass grafts: the Coronary Artery Surgery Study (CASS)
and Montreal Heart Institute experiences. Circulation
1985;72:V71-8.
325. FitzGibbon GM, Leach AJ, Kafka
HP, Keon WJ. Coronary bypass graft fate: long-term angiographic
study. J Am Coll Cardiol 1991;17:1075-80.
326. ACC/AHA guidelines and indications
for coronary artery bypass graft surgery: a report of
the American College of Cardiology/American Heart Association
Task Force on Assessment of Diagnostic and Therapeutic
Cardiovascular Procedures (Subcommittee on Coronary Artery
Bypass Graft Surgery). J Am Coll Cardiol 1999;34:1262-1341.
327. Hwang MH, Meadows WR, Palac RT,
et al. Progression of coronary artery disease in medically
and surgically treated patients 5 years after randomization.
J Am Coll Cardiol 1998;16:1066-70.
328. Weintraub WS, Jones EL, Craver
JM, Guyton RA. Frequency of repeat coronary bypass or
coronary angioplasty after coronary artery bypass surgery
using saphenous venous grafts. Am J Cardiol 1994;73:103-12.
329. Okies JE, Page US, Bigelow JC,
Krause AH, Salomon NW. The left internal mammary artery:
the graft of choice. Circulation 1984;70:I213-21.
330. Tector AJ, Schmahl TM, Canino
VR. The internal mammary artery graft: the best choice
for bypass of the diseased left anterior descending coronary
artery. Circulation 1983;68:II214-7.
331. Loop FD, Lytle BW, Cosgrove DM,
et al. Reoperation for coronary atherosclerosis: changing
practice in 2509 consecutive patients. Ann Surg 1990;212:378-85.
332. Verheul HA, Moulijn AC, Hondema
S, Schouwink M, Dunning AJ. Late results of 200 repeat
coronary artery bypass operations. Am J Cardiol 1991;67:24-30.
333. Hannan EL, Kilburn HJ, O'Donnell
JF, Lukacik G, Shields EP. Adult open heart surgery in
New York State: an analysis of risk factors and hospital
mortality rates. JAMA 1990;264:2768-74.
334. Lytle BW, Loop FD, Cosgrove DM,
et al. Fifteen hundred coronary reoperations: results
and determinants of early and late survival. J Thorac
Cardiovasc Surg 1987;93:847-859.
335. Cameron A, Kemp HG Jr, Green GE.
Reoperation for coronary artery disease: 10 years of clinical
follow-up. Circulation 1998;78:I158-62.
336. Campeau L, Lesperance J, Bourassa
MG. Natural history of saphenous vein aortacoronary bypass
grafts. Mod Concepts Cardiovasc Dis 1984;54:59-63.
337. Bourassa MG. Fate of venous grafts:
the past, the present and the future. J Am Coll Cardiol
1991;17:1081-83.
338. FitzGibbon GM, Kafka HP, Leach
AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft
fate and patient outcome: angiographic follow-up of 5,065
grafts related to survival and reoperation in 1,388 patients
during 25 years. J Am Coll Cardiol 1996;28:616-26.
339. Cox JL, Chiasson DA, Gotlieb AI.
Stranger in a strange land: the pathogenesis of saphenous
vein graft stenosis with emphasis on structural and functional
differences between veins and arteries. Prog Cardiovasc Dis 1991;34:45-68.
340. Kahn JK, Rutherford BD, McConahay
DR, et al. Early postoperative balloon coronary angioplasty
for failed coronary artery bypass grafting. Am J Cardiol
1990;66:943-46.
341. Dimas AP, Arora RR, Whitlow PL,
et al. Percutaneous transluminal angioplasty involving
internal mammary artery grafts. Am Heart J 1991;122:423-9.
342. Dorogy ME, Highfill WT, Davis
RC. Use of angioplasty in the management of complicated
perioperative infarction following bypass surgery. Cathet Cardiovasc Diagn 1993;29:279-82.
343. Rentrop P, Blanke H, Karsch KR,
Kostering H, Oster H, Leitz H. Recanalization of an acutely
occluded aortocoronary bypass by intragraft fibrinolysis.
Circulation 1980;62:1123-6.
344. Holmes DR Jr, Chesebro JH, Vlietstra
RE, Orszulak TA. Streptokinase for vein graft thrombosis:
a caveat. Circulation 1981;63:729.
345. Marx M, Armstrong WP, Wack JP,
et al. Short-duration, high-dose urokinase infusion for
recanalization of occluded saphenous aortocoronary bypass
grafts. Am J Roentgenol 1989;153:167-71.
346. Hartzler GO, Johnson WL, McConahay
DR, et al. Dissolution of coronary artery bypass graft
thrombi by streptokinase infusion. Am J Cardiol 1981;47:493.
347. Van Ommen VG, van den Bos AA,
Pieper M, et al. Removal of thrombus from aortocoronary
bypass grafts and coronary arteries using the 6Fr Hydrolyser.
Am J Cardiol 1997;79:1012-6.
348. Douglas JS Jr Gruentzig AR, King
SB III, et al. Percutaneous transluminal coronary angioplasty
in patients with prior coronary bypass surgery. J Am Coll Cardiol 1983;2:745-54.
349. Reeves F, Bonan R, Cote G, et
al. Long-term angiographic follow-up after angioplasty
of venous coronary bypass grafts. Am Heart J 1991;122:620-7.
350. Meester BJ, Samson M, Suryapranata
H, et al. Long-term follow-up after attempted angioplasty
of saphenous vein grafts: the Thoraxcenter experience
1981-1988. Eur Heart J 1991;12:648-53.
351. de Feyter PJ, van Suylen RJ, de
Jaegere PP, Topol EJ, Serruys PW. Balloon angioplasty
for the treatment of lesions in saphenous vein bypass
grafts. J Am Coll Cardiol 1993;21:1539-49.
352. Gruberg L, Hong MK, Mehran R,
et al. In-hospital and long-term results of stent deployment
compared with balloon angioplasty for treatment of narrowing
at the saphenous vein graft distal anastomosis site. Am
J Cardiol 1999;84:1381-4.
353. Strauss BH, Natarajan MK, Batchelor
WB, et al. Early and late quantitative angiographic results
of vein graft lesions treated by excimer laser with adjunctive
balloon angioplasty. Circulation 1995;92:348-56.
354. Bittl JA, Sanborn TA, Yardley
DE, et al. Predictors of outcome of percutaneous excimer
laser coronary angioplasty of saphenous vein bypass graft
lesions: the Percutaneous Excimer Laser Coronary Angioplasty
Registry. Am J Cardiol 1994;74:144-8.
355. Stullman WS, Hilliard GK. Unrecognized
internal mammary artery stenosis treated by percutaneous
angioplasty after coronary bypass surgery. Am Heart J
1987;113:393-5.
356. Vivekaphirat V, Yellen SF, Foschi
A. Percutaneous transluminal angioplasty of a stenosis
at the origin of the left internal mammary artery graft:
a case report. Cathet Cardiovasc Diagn 1988;15:176-8.
357. Sketch MHJ, Quigley PJ, Perez
JA, et al. Angiographic follow-up after internal mammary
artery graft angioplasty. Am J Cardiol 1992;70:401-3.
358. Popma JJ, Cooke RH, Leon MB, et
al. Immediate procedural and long-term clinical results
of internal mammary artery angioplasty. Am J Cardiol 1992;69:1237-9.
359. Isshiki T, Yamaguchi T, Tamura
T, et al. Percutaneous angioplasty of stenosed gastroepiploic
artery grafts. J Am Coll Cardiol 1993;22:727-32.
360. Breall JA, Grossman W, Stillman
IE, Gianturco LE, Kim D. Atherectomy of the subclavian
artery for patients with symptomatic coronary-subclavian
steal syndrome. J Am Coll Cardiol 1993;21:1564-7.
361. Perrault LP, Carrier M, Hudon
G, Lemarbre L, Hebert Y, Pelletier LC. Transluminal angioplasty
of the subclavian artery in patients with internal mammary
grafts. Ann Thorac Surg 1993;56:927-30.
362. Tan KH, Henderson RA, Sulke N,
Cooke RA, Karani S, Sowton E. Percutaneous transluminal
coronary angioplasty in patients with prior coronary artery
bypass grafting: ten years' experience. Cathet Cardiovasc Diagn 1994;32:11-7.
363. Hong MK, Mehran R, Dangas G, et
al. Creatine kinase-MB enzyme elevation following successful
saphenous vein graft intervention is associated with late
mortality. Circulation 1999;100:2400-5.
364. Abbo KM, Dooris M, Glazier S,
et al. Features and outcome of no-reflow after percutaneous
coronary intervention. Am J Cardiol 1995;75:778-82.
365. Liu MW, Douglas JS Jr, Lembo NJ,
King SB III. Angiographic predictors of a rise in serum
creatine kinase (distal embolization) after balloon angioplasty
of saphenous vein coronary artery bypass grafts. Am J
Cardiol 1993;72:514-7.
366. Meany TB, Leon MB, Kramer BL,
et al. Transluminal extraction catheter for the treatment
of diseased saphenous vein grafts: a multicenter experience.
Cathet Cardiovasc Diagn 1995;34:112-20.
367. Safian RD, Grines CL, May MA,
et al. Clinical and angiographic results of transluminal
extraction coronary atherectomy in saphenous vein bypass
grafts. Circulation 1994;89:302-12.
368. Dooris M, Hoffmann M, Glazier
S, et al. Comparative results of transluminal extraction
coronary atherectomy in saphenous vein graft lesions with
and without thrombus. J Am Coll Cardiol 1995;25:1700-5.
369. Kaplan BM, Safian RD, Grines CL,
et al. Usefulness of adjunctive angioscopy and extraction
atherectomy before stent implantation in high-risk aortocoronary
saphenous vein grafts. Am J Cardiol 1995;76:822-4.
370. Hong MK, Popma JJ, Pichard AD,
et al. Clinical significance of distal embolization after
transluminal extraction atherectomy in diffusely diseased
saphenous vein grafts. Am Heart J 1994;127:1496-503.
371. Weyrens FJ, Mooney J, Lesser J,
Mooney MR. Intracoronary diltiazem for microvascular spasm
after interventional therapy. Am J Cardiol 1995;75:849-50.
372. Mak KH, Challapalli R, Eisenberg
MJ, Anderson KM, Califf RM, Topol EJ. Effect of platelet
glycoprotein IIb/IIIa receptor inhibition on distal embolization
during percutaneous revascularization of aortocoronary
saphenous vein grafts. Am J Cardiol 1997;80:985-8.
373. Stephan WJ, Bates ER, Garratt
KN, Hinohara T, Muller DW. Directional atherectomy of
coronary and saphenous vein graft ostial stenoses. Am
J Cardiol 1995;75:1015-8.
374. Cowley MJ, Whitlow PL, Baim DS,
Hinohara T, Hall K, Simpson JB. Directional coronary atherectomy
of saphenous vein graft narrowings: multicenter investigational
experience. Am J Cardiol 1993;72:30E-4E.
375. Abdelmeguid AE, Whitlow PL, Simpfendorfer
C, et al. Percutaneous revascularization of ostial saphenous
vein graft stenoses. J Am Coll Cardiol 1995;26:955-60.
376. Rechavia E, Litvack F, Macko G,
Eigler NL. Stent implantation of saphenous vein graft
aorto-ostial lesions in patients with unstable ischemic
syndromes: immediate angiographic results and long-term
clinical outcome. J Am Coll Cardiol 1995;25:866-70.
377. Wong SC, Popma JJ, Pichard AD,
et al. Comparison of clinical and angiographic outcomes
after saphenous vein graft angioplasty using coronary
versus 'biliary' tubular slotted stents. Circulation 1995;91:339-50.
378. Eeckhout E, Goy JJ, Stauffer JC,
Vogt P, Kappenberger L. Endoluminal stenting of narrowed
saphenous vein grafts: long-term clinical and angiographic
follow-up. Cathet Cardiovasc Diagn 1994;32:139-46.
379. Keane D, Buis B, Reifart N, et
al. Clinical and angiographic outcome following implantation
of the new Less Shortening Wallstent in aortocoronary
vein grafts: introduction of a second generation stent
in the clinical arena. J Interv Cardiol 1994;7:557-64.
380. Fenton SH, Fischman DL, Savage
MP, et al. Long-term angiographic and clinical outcome
after implantation of balloon-expandable stents in aortocoronary
saphenous vein grafts. Am J Cardiol 1994;74:1187-91.
381. Piana RN, Moscucci M, Cohen DJ,
et al. Palmaz-Schatz stenting for treatment of focal vein
graft stenosis: immediate results and long-term outcome.
J Am Coll Cardiol 1994;23:1296-304.
382. Ellis SG, Brener SJ, DeLuca S,
et al. Late myocardial ischemic events after saphenous
vein graft intervention: importance of initially "nonsignificant"
vein graft lesions. Am J Cardiol 1997;79:1460-4.
383. de Jaegere P, van Domburg RT,
Feyter PJ, et al. Long-term clinical outcome after stent
implantation in saphenous vein grafts. J Am Coll Cardiol
1996;28:89-96.
384. Hong MK, Mehran R, Dangas G, et
al. Comparison of time course of targe lesion revascularization
following successful saphenous vein graft angioplasty
versus successful native coronary angioplasty. Am J Cardiol
2000;85:256-8.
385. Kahn JK, Rutherford BD, McConahay
DR, et al. Initial and long-term outcome of 83 patients
after balloon angioplasty of totally occluded bypass grafts.
J Am Coll Cardiol 1994;23:1038-42.
386. Hartmann JR, McKeever LS, Stamato
NJ, et al. Recanalization of chronically occluded aortocoronary
saphenous vein bypass grafts by extended infusion of urokinase:
initial results and short-term clinical follow-up. J Am Coll Cardiol 1991;18:1517-23.
387. Hartmann JR, McKeever LS, O'Neill
WW, et al. Recanalization of chronically occluded aortocoronary
saphenous vein bypass grafts with long-term, low dose
direct infusion of urokinase (ROBUST): a serial trial.
J Am Coll Cardiol 1996;27:60-6.
388. Denardo SJ, Morris NB, Rocha-Singh
KJ, Curtis GP, Rubenson DS, Teirstein PS. Safety and efficacy
of extended urokinase infusion plus stent deployment for
treatment of obstructed, older saphenous vein grafts.
Am J Cardiol 1995;76:776-80.
389. McKeever LS, Hartmann JR, Bufalino
VJ, et al. Acute myocardial infarction complicating recanalization
of aortocoronary bypass grafts with urokinase therapy.
Am J Cardiol 1989;64:683-5.
390. Blankenship JC, Modesto TA, Madigan
NP. Acute myocardial infarction complicating urokinase
infusion for total saphenous vein graft occlusion. Cathet Cardiovasc Diagn 1993;28:39-43.
391. Gurley JC, MacPhail BS. Acute
myocardial infarction due to thrombolytic reperfusion
of chronically occluded saphenous vein coronary bypass
grafts. Am J Cardiol 1991;68:274-5.
392. Margolis JR, Mogensen L, Mehta
S, Chen CY, Krauthamer D. Diffuse embolization following
percutaneous transluminal coronary angioplasty of occluded
vein grafts: the blush phenomenon. Clin Cardiol 1991;14:489-93.
393. Taylor MA, Santoian EC, Aji J,
Eldredge WJ, Cha SD, Dennis CA. Intracerebral hemorrhage
complicating urokinase infusion into an occluded aortocoronary
bypass graft. Cathet Cardiovasc Diagn 1994;31:206-10.
394. Bedotto JB, Rutherford BD, Hartzler
GO. Intramyocardial hemorrhage due to prolonged intracoronary
infusion of urokinase into a totally occluded saphenous
vein bypass graft. Cathet Cardiovasc Diagn 1992;25:52-6.
395. Chapekis AT, George BS, Candela
RJ. Rapid thrombus dissolution by continuous infusion
of urokinase through an intracoronary perfusion wire prior
to and following PTCA: results in native coronaries and
patent saphenous vein grafts. Cathet Cardiovasc Diagn
1991;23:89-92.
396. Sabri MN, Johnson D, Warner M,
Cowley MJ. Intracoronary thrombolysis followed by directional
atherectomy: a combined approach for thrombotic vein graft
lesions considered unsuitable for angioplasty. Cathet Cardiovasc Diagn 1992;26:15-8.
397. Whisenant BK, Baim DS, Kuntz RE,
Garcia LA, Ramee SR, Carrozza JP. Rheolytic Thrombectomy
with the Possis AngioJet : Technical Considerations and
Initial Clinical Experience. J Invasive Cardiol 1999;11:421-6.
398. El Gamal M, Bonnier H, Michels
R, Heijman J, Stassen E. Percutaneous transluminal angioplasty
of stenosed aortocoronary bypass grafts. Br Heart J 1984;52:617-20.
399. Block PC, Cowley MJ, Kaltenbach
M, Kent KM, Simpson J. Percutaneous angioplasty of stenoses
of bypass grafts or of bypass graft anastomotic sites.
Am J Cardiol 1984;53:666-8.
400. Dorros G, Johnson WD, Tector AJ,
Schmahl TM, Kalush SL, Janke L. Percutaneous transluminal
coronary angioplasty in patients with prior coronary artery
bypass grafting. J Thorac Cardiovasc Surg 1984;87:17-26.
401. Corbelli J, Franco I, Hollman
J, Simpfendorfer C, Galan K. Percutaneous transluminal
coronary angioplasty after previous coronary artery bypass
surgery. Am J Cardiol 1985;56:398-403.
402. Reeder GS, Bresnahan JF, Holmes
DR Jr, et al. Angioplasty for aortocoronary bypass graft
stenosis. Mayo Clin Proc 1986;61:14-9.
403. Cote G, Myler RK, Stertzer SH,
et al. Percutaneous transluminal angioplasty of stenotic
coronary artery bypass grafts: 5 years' experience. J Am Coll Cardiol 1987;9:8-17.
404. Ernst SM, van der Feltz TA, Ascoop
CA, et al. Percutaneous transluminal coronary angioplasty
in patients with prior coronary artery bypass grafting.
J Thorac Cardiovasc Surg 1987;93:268-75.
405. Pinkerton CA, Slack JD, Orr CM,
VanTassel JW, Smith ML. Percutaneous transluminal angioplasty
in patients with prior myocardial revascularization surgery.
Am J Cardiol 1988;61:15G-22G.
406. Dorros G, Lewin RF, Mathiak LM,
et al. Percutaneous transluminal coronary angioplasty
in patients with two or more previous coronary artery
bypass grafting operations. Am J Cardiol 1988;61:1243-7.
407. Reed DC, Beller GA, Nygaard TW,
Tedesco C, Watson DD, Burwell LR. The clinical efficacy
and scintigraphic evaluation of post- coronary bypass
patients undergoing percutaneous transluminal coronary
angioplasty for recurrent angina pectoris. Am Heart J
1989;117:60-71.
408. Cooper I, Ineson N, Demirtas E,
Coltart J, Jenkins S, Webb-Peploe M. Role of angioplasty
in patients with previous coronary artery bypass surgery.
Cathet Cardiovasc Diagn 1989;16:81-6.
409. Platko WP, Hollman J, Whitlow
PL, Franco I. Percutaneous transluminal angioplasty of
saphenous vein graft stenosis: long-term follow-up. J Am Coll Cardiol 1989;14:1645-50.
410. Kussmaul WG. Percutaneous angioplasty
of coronary bypass grafts: an emerging consensus. Cathet Cardiovasc Diagn 1988;15:1-4.
411. Lytle BW, McElroy D, McCarthy
P, et al. Influence of arterial coronary bypass grafts
on the mortality in coronary reoperations. J Thorac Cardiovasc
Surg 1994;107:675-82.
412. Mishra YK, Mehta Y, Juneja R,
Kasliwal RR, Mittal S, Trehan N. Mammary-coronary artery
anastomosis without cardiopulmonary bypass through a minithoracotomy.
Ann Thorac Surg 1997;63:S114-S8
413. Allen KB, Matheny RG, Robison
RJ, Heimansohn DA, Shaar CJ. Minimally invasive versus
conventional reoperative coronary artery bypass. Ann Thorac
Surg 1997;64:616-22.
414. Calafiore AM, Giammarco GD, Teodori
G, et al. Left anterior descending coronary artery grafting
via left anterior small thoracotomy without cardiopulmonary
bypass. Ann Thorac Surg 1996;61:1658-63.
415. Boonstra PW, Grandjean JG, Mariani
MA. Reoperative coronary bypass grafting without cardiopulmonary
bypass through a small thoracotomy. Ann Thorac Surg 1997;63:405-7.
416. Grossi EA, Groh MA, Lefrak EA,
et al. Results of a prospective multicenter study on port-access
coronary bypass grafting. Ann Thorac Surg 1999;68:1475-7.
417. Cohen HA, Zenati M. Integrated
Coronary Revascularization. J Invasive Cardiol 1999;11:184-91.
418. Angelini GD, Wilde P, Salerno
TA, Bosco G, Calafiore AM. Integrated left small thoracotomy
and angioplasty for multivessel coronary artery revascularisation
[letter]. Lancet 1996;347:757-8.
419. Cavender JB, Rogers WJ, Fisher
LD, Gersh BJ, Coggin CJ, Myers WO. Effects of smoking
on survival and morbidity in patients randomized to medical
or surgical therapy in the Coronary Artery Surgery Study
(CASS): 10-year follow-up. CASS Investigators. J Am Coll Cardiol 1992;20:287-94.
420. Voors AA, van Brussel BL, Plokker
HW, et al. Smoking and cardiac events after venous coronary
bypass surgery: a 15-year follow-up study. Circulation
1996;93:42-7.
421. Sacks FM, Pfeffer MA, Moye LA,
et al. The effect of pravastatin on coronary events after
myocardial infarction in patients with average cholesterol
levels. Cholesterol and Recurrent Events Trial investigators.
N Engl J Med 1996;335:1001-9.
422. The effect of aggressive lowering
of low-density lipoprotein cholesterol levels and low-dose
anticoagulation on obstructive changes in saphenous-vein
coronary-artery bypass grafts. The Post Coronary Artery
Bypass Graft Trial Investigators [published erratum appears
in N Engl J Med 1997;337:1859]. N Engl J Med 1997;336:153-62.
423. Colombo A, Hall P, Nakamura S,
et al. Intracoronary stenting without anticoagulation
accomplished with intravascular ultrasound guidance. Circulation
1995;91:1676-88.
424. Kern MJ, Dupouy P, Drury JH, et
al. Role of coronary artery lumen enlargement in improving
coronary blood flow after balloon angioplasty and stenting:
a combined intravascular ultrasound Doppler flow and imaging
study. J Am Coll Cardiol 1997;29:1520-7.
425. Tobis J, Colombo A. IVUS and coronary
stenting. Cathet Cardiovasc Diagn 1996;39:346.
426. Yock PG, Fitzgerald PJ, Linker
DT, Angelsen BA. Intravascular ultrasound guidance for
catheter-based coronary interventions. J Am Coll Cardiol
1991;17:39B-45B.
427. Mudra H, Klauss V, Blasini R,
et al. Ultrasound guidance of Palmaz-Schatz intracoronary
stenting with a combined intravascular ultrasound balloon
catheter. Circulation 1994;90:1252-61.
428. Nakamura S, Colombo A, Gaglione
A, et al. Intracoronary ultrasound observations during
stent implantation. Circulation 1994;89:2026-34.
429. Karrillon GJ, Morice MC, Benveniste
E, et al. Intracoronary stent implantation without ultrasound
guidance and with replacement of conventional anticoagulation
by antiplatelet therapy: 30-day clinical outcome of the
French Multicenter Registry. Circulation 1996;94:1519-27.
430. Moussa I, Moses J, Di Mario C,
et al. Does the specific intravascular ultrasound criterion
used to optimize stent expansion have an impact on the
probability of stent restenosis? Am J Cardiol 1999;83:1012-7.
431. Fitzgerald PJ, Oshima A, Hayase
M, et al. Final results of the Can Routine Ultrasound
Influence Stent Expansion (CRUISE) study. Circulation
2000;102:523-30.
432. Donohue TJ, Kern MJ, Aguirre FV,
et al. Assessing the hemodynamic significance of coronary
artery stenoses: analysis of translesional pressure-flow
velocity relations in patients. J Am Coll Cardiol 1993;22:449-58.
433. Miller DD, Donohue TJ, Younis
LT, et al. Correlation of pharmacological 99mTc-sestamibi
myocardial perfusion imaging with poststenotic coronary
flow reserve in patients with angiographically intermediate
coronary artery stenoses. Circulation 1994;89:2150-60.
434. Heller LI, Cates C, Popma J, et
al. Intracoronary Doppler assessment of moderate coronary
artery disease: comparison with 201Tl imaging and coronary
angiography. FACTS Study Group. Circulation 1997;96:484-90.
435. Baumgart D, Haude M, Goerge G,
et al. Improved assessment of coronary stenosis severity
using the relative flow velocity reserve. Circulation
1998;98:40-6.
436. Pijls NH, Van Gelder B, Van der
Voort P, et al. Fractional flow reserve: a useful index
to evaluate the influence of an epicardial coronary stenosis
on myocardial blood flow. Circulation 1995;92:3183-93.
437. Kern MJ, Donohue TJ, Aguirre FV,
et al. Clinical outcome of deferring angioplasty in patients
with normal translesional pressure-flow velocity measurements.
J Am Coll Cardiol 1995;25:178-187.
438. Pijls NH, De Bruyne B, Peels K,
et al. Measurement of fractional flow reserve to assess
the functional severity of coronary-artery stenoses. N Engl J Med 1996;334:1703-8.
439. Bech GJ, Pijls NH, De Bruyne B,
et al. Usefulness of Fractional Flow Reserve to Predict
Clinical Outcome After Balloon Angioplasty. Circulation
1999;99:883-8.
440. Pijls NH, van Son JA, Kirkeeide
RL, De Bruyne B, Gould KL. Experimental basis of determining
maximum coronary, myocardial, and collateral blood flow
by pressure measurements for assessing functional stenosis
severity before and after percutaneous transluminal coronary
angioplasty. Circulation 1993;87:1354-67.
441. De Bruyne B, Bartunek J, Sys SU,
Heyndrickx GR. Relation between myocardial fractional
flow reserve calculated from coronary pressure measurements
and exercise-induced myocardial ischemia. Circulation
1995;92:39-46.
442. Serruys PW, Di Mario C, Piek J,
et al. Prognostic value of intracoronary flow velocity
and diameter stenosis in assessing the short- and long-term
outcomes of coronary balloon angioplasty: the DEBATE Study
(Doppler Endpoints Balloon Angioplasty Trial Europe).
Circulation 1997;96:3369-77.
443. Baim DS, Hinohara T, Holmes D,
et al. Results of directional coronary atherectomy during
multicenter preapproval testing: the US Directional Coronary
Atherectomy Investigator Group. Am J Cardiol 1993;72:6E-11E.
444. Warth DC, Leon MB, O'Neill W,
Zacca N, Polissar NL, Buchbinder M. Rotational atherectomy
multicenter registry: acute results, complications and
6-month angiographic follow-up in 709 patients. J Am Coll Cardiol 1994;24:641-8.
445. Popma JJ, Brogan WC3, Pichard
AD, et al. Rotational coronary atherectomy of ostial stenoses.
Am J Cardiol 1993;71:436-8.
446. Jain SP, Liu MW, Dean LS, et al.
Comparison of balloon angioplasty versus debulking devices
versus stenting in right coronary ostial lesions. Am J
Cardiol 1997;79:1334-8.
447. Ahmed WH, al-Anazi MM, Bittl JA.
Excimer laser-facilitated angioplasty for undilatable
coronary narrowings. Am J Cardiol 1996;78:1045-6.
448. Safian RD, Freed M, Reddy V, et
al. Do excimer laser angioplasty and rotational atherectomy
facilitate balloon angioplasty? Implications for lesion-specific
coronary intervention. J Am Coll Cardiol 1996;27:552-9.
449. Appelman YE, Koolen JJ, Piek JJ,
et al. Excimer laser angioplasty versus balloon angioplasty
in functional and total coronary occlusions. Am J Cardiol
1996;78:757-62.
450. Reifart N, Vandormael M, Krajcar
M, et al. Randomized comparison of angioplasty of complex
coronary lesions at a single center: Excimer Laser, Rotational
Atherectomy, and Balloon Angioplasty Comparison (ERBAC)
Study. Circulation 1997;96:91-8.
451. Appelman YE, Piek JJ, Strikwerda
S, et al. Randomised trial of excimer laser angioplasty
versus balloon angioplasty for treatment of obstructive
coronary artery disease. Lancet 1996;347:79-84.
452. Bittl JA. Excimer laser angioplasty:
focus on total occlusions. Am J Cardiol 1996;78:823-4.
453. Lembo NJ, Black AJ, Roubin GS,
et al. Effect of pretreatment with aspirin versus aspirin
plus dipyridamole on frequency and type of acute complications
of percutaneous transluminal coronary angioplasty. Am
J Cardiol 1990;65:422-6.
454. Timmermans C, Vrolix M, Vanhaecke
J, et al. Ridogrel in the setting of percutaneous transluminal
coronary angioplasty. Am J Cardiol 1991;68:463-6.
455. Knudtson ML, Flintoft VF, Roth
DL, Hansen JL, Duff HJ. Effect of short-term prostacyclin
administration on restenosis after percutaneous transluminal
coronary angioplasty. J Am Coll Cardiol 1990;15:691-7.
456. Gregorini L, Marco J, Fajadet
J, et al. Ticlopidine and aspirin pretreatment reduces
coagulation and platelet activation during coronary dilation
procedures. J Am Coll Cardiol 1997;29:13-20.
457. A randomised, blinded, trial of
clopidogrel versus aspirin in patients at risk of ischaemic
events (CAPRIE): CAPRIE Steering Committee. Lancet 1996;348:1329-39.
458. Hearn JA, King SB, III, Douglas
JSJ, Carlin SF, Lembo NJ, Ghazzal ZM. Clinical and angiographic
outcomes after coronary artery stenting for acute or threatened
closure after percutaneous transluminal coronary angioplasty:
initial results with a balloon-expandable, stainless steel
design. Circulation 1993;88:2086-96.
459. Goldberg SL, Colombo A, Nakamura
S, Almagor Y, Maiello L, Tobis JM. Benefit of intracoronary
ultrasound in the deployment of Palmaz- Schatz stents.
J Am Coll Cardiol 1994;24:996-1003.
460. Hall P, Colombo A, Almagor Y,
et al. Preliminary experience with intravascular ultrasound
guided Palmaz-Schatz coronary stenting: the acute and
short-term results on a consecutive series of patients.
J Interv Cardiol 1994;7:141-59.
461. Schomig A, Neumann FJ, Kastrati
A, et al. A randomized comparison of antiplatelet and
anticoagulant therapy after the placement of coronary-artery
stents. N Engl J Med 1996;334:1084-9.
462. Urban P, Macaya C, Rupprecht HJ,
et al. Randomized evaluation of anticoagulation versus
antiplatelet therapy after coronary stent implantation
in high-risk patients: the multicenter aspirin and ticlopidine
after intracoronary stenting (MATTIS). Circulation 1998;98:2126-32.
463. Steinhubl SR, Lauer MS, Mukerjee
DP, Moliterno DJ, Ellis SG, Topol EJ. The duration of
pretreatment with ticlopidine prior to stenting is associated
with the risk of procedure-related non-Q-wave myocardial
infarctions. J Am Coll Cardiol 1998;32:1366-70.
464. Hass WK, Easton JD, Adams HPJ,
et al. A randomized trial comparing ticlopidine hydrochloride
with aspirin for the prevention of stroke in high-risk
patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501-7.
465. Rodriguez JN, Fernandez-Jurado
A, Dieguez JC, Amian A, Prados D. Ticlopidine and severe
aplastic anemia [letter]. Am J Hematol 1994;47:332.
466. Bellavance A. Efficacy of ticlopidine
and aspirin for prevention of reversible cerebrovascular
ischemic events: the Ticlopidine Aspirin Stroke Study.
Stroke 1993;24:1452-7.
467. Page Y, Tardy B, Zeni F, Comtet
C, Terrana R, Bertrand JC. Thrombotic thrombocytopenic
purpura related to ticlopidine. Lancet 1991;337:774-6.
468. Kupfer Y, Tessler S. Ticlopidine
and thrombotic thrombocytopenic purpura [letter]. N Engl J Med 1997;337:1245.
469. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror
K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic
purpura associated with ticlopidine: a review of 60 cases.
Ann Intern Med 1998;128:541-4.
470. Szto GYT, Linnemeier TJ, Lewis
SJ, et al. Safety of 10 days of ticlopidine after coronary
stenting: a randomized comparison with 30 days: Strategic
ALternatives with Ticlopidine in Stenting Study (SALTS).
J Am Coll Cardiol 1998;31:352A (Abstract).
471. Berger PB, Bell MR, Hasdai D,
Grill DE, Melby S, Holmes DR Jr. Safety and efficacy of
ticlopidine for only 2 weeks after successful intracoronary
stent placement. Circulation 1999;99:248-53.
472. Moussa I, Oetgen M, Roubin G,
et al. Effectiveness of clopidogrel and aspirin versus
ticlopidine and aspirin in preventing stent thrombosis
after coronary stent implantation. Circulation. 1999;99:2364-6.
473. Berger PB, Bell MR, Rihal CS,
et al. Clopidogrel versus ticlopidine after intracoronary
stent placement. J Am Coll Cardiol 1999;34:1891-4.
474. Mishkel GJ, Aguirre FV, Ligon
RW, Rocha-Singh KJ, Lucore CL. Clopidogrel as adjunctive
antiplatelet therapy during coronary stenting. J Am Coll Cardiol 1999;34:1884-90.
475. Muller C, Buttner HJ, Petersen
J, Roskamm H. A randomized comparison of clopidogrel and
aspirin versus ticlopidine and aspirin after the placement
of coronary-artery stents. Circulation 2000;101:590-3.
476. Gasperetti CM, Gonias SL, Gimple
LW, Powers ER. Platelet activation during coronary angioplasty
in humans. Circulation 1993;88:2728-34.
477. Anderson HV, Kirkeeide RL, Krishnaswami
A, et al. Cyclic flow variations after coronary angioplasty
in humans: clinical and angiographic characteristics and
elimination with 7E3 monoclonal antiplatelet antibody.
J Am Coll Cardiol 1994;23:1031-7.
478. Use of a monoclonal antibody directed
against the platelet glycoprotein IIb/IIIa receptor in
high-risk coronary angioplasty: the EPIC Investigation.
N Engl J Med 1994;330:956-61.
479. Topol EJ, Ferguson JJ, Weisman
HF, et al. Long-term protection from myocardial ischemic
events in a randomized trial of brief integrin beta3 blockade
with percutaneous coronary intervention. EPIC Investigator
Group. Evaluation of Platelet IIb/IIIa Inhibition for
Prevention of Ischemic Complication. JAMA 1997;278:479-84.
480. Brener SJ, Barr LA, Burchenal
JE, et al. Randomized, placebo-controlled trial of platelet
glycoprotein IIb/IIIa blockade with primary angioplasty
for acute myocardial infarction. ReoPro and Primary PTCA
Organization and Randomized Trial (RAPPORT) Investigators.
Circulation 1998;98:734-41.
481. Kereiakes DJ, Lincoff AM, Miller
DP, et al. Abciximab therapy and unplanned coronary stent
deployment: favorable effects on stent use, clinical outcomes,
and bleeding complications. EPILOG Trial Investigators.
Circulation 1998;97:857-64.
482. Topol EJ, Mark DB, Lincoff AM,
et al. Outcomes at 1 year and economic implications of
platelet glycoprotein IIb/IIIa blockade in patients undergoing
coronary stenting: results from a multicentre randomised
trial. EPISTENT Investigators. Evaluation of Platelet
IIb/IIIa Inhibitor for Stenting. Lancet 1999;354:2019-24.
483. Heeschen C, Hamm CW, Bruemmer
J, Simoons ML. Predictive value of C-reactive protein
and troponin T in patients with unstable angina: a comparative
analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet
Therapy in Unstable angina REfractory to standard treatment
trial. J Am Coll Cardiol 2000;35:1535-42.
484. Hamm CW, Heeschen C, Goldmann
B, et al. Benefit of abciximab in patients with refractory
unstable angina in relation to serum troponin T levels.
c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina
(CAPTURE) Study Investigators [published erratum appears
in N Engl J Med 1999;34:548]. N Engl J Med 1999;340:1623-9.
485. Madan M, Kereiakes DJ, Hermiller
JB, et al. Efficacy of abciximab readministration in coronary
intervention. Am J Cardiol 2000;85:435-40.
486. Randomised placebo-controlled
trial of abciximab before and during coronary intervention
in refractory unstable angina: the CAPTURE Study [published
erratum appears in Lancet 1997;350:744]. Lancet 1997;349:1429-35.
487. Bhatt DL, Lincoff AM, Kereiakes
DJ, et al. Reduction in the need for unplanned stenting
with the use of platelet glycoprotein IIb/IIIa blockade
in percutaneous coronary intervention. Am J Cardiol 1998;82:1105-6,
A6.
488. Tcheng JE, Kereiakes DJ, Braden
GA, et al. Safety of abciximab retreatment: final clinical
report of the ReoPro readministration registry (R3). Circulation
1998;98 (Suppl):I-17.
489. Randomised placebo-controlled
trial of effect of eptifibatide on complications of percutaneous
coronary intervention: IMPACT-II. Integrilin to Minimise
Platelet Aggregation and Coronary Thrombosis-II. Lancet
1997;349:1422-8.
490. Inhibition of platelet glycoprotein
IIb/IIIa with eptifibatide in patients with acute coronary
syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein
IIb/IIIa in Unstable Angina: Receptor Suppression Using
Integrilin Therapy. N Engl J Med 1998;339:436-43.
491. Novel dosing regimen of eptifibatide
in planned coronary stent implantation (ESPRIT): a randomised,
placebo-controlled trial. Lancet 2000;356:2037-44.
492. O'shea JC, Madan M, Cantor WJ,
et al. Design and methodology of the ESPRIT trial: evaluating
a novel dosing regimen eptifibatide in percutaneous coronary
intervention. Am Heart J 2000;140:834-9.
493. Peerlinck K, De Lepeleire I, Goldberg
M, et al. MK-383 (L-700,462), a selective nonpeptide platelet
glycoprotein IIb/IIIa antagonist, is active in man. Circulation
1993;88:1512-7.
494. Effects of platelet glycoprotein
IIb/IIIa blockade with tirofiban on adverse cardiac events
in patients with unstable angina or acute myocardial infarction
undergoing coronary angioplasty: the RESTORE Investigators.
Randomized Efficacy Study of Tirofiban for Outcomes and
Restenosis. Circulation 1997;96:1445-53.
495. Barr E, Snapinn SM, Sax FL, Theroux
P. Improved long-term clinical outcomes in unstable angina
patients undergoing coronary angioplasty following therapy
with tirofiban and heparin. J Am Coll Cardiol 1998;31:55A
(Abstract).
496. Bhatt DL, Marso SP, Lincoff AM,
Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality
in diabetics following percutaneous coronary intervention.
J Am Coll Cardiol 2000;35:922-8.
497. Topol EJ, Byzova TV, Plow EF.
Platelet GP IIb/IIIa blockers. Lancet 1999;353:227-31.
498. Topol EJ, Bonan R, Jewitt D, et
al. Use of a direct antithrombin, hirulog, in place of
heparin during coronary angioplasty. Circulation 1993;87:1622-9.
499. Grayburn PA, Willard JE, Brickner
ME, Eichhorn EJ. In vivo thrombus formation on a guidewire
during intravascular ultrasound imaging: evidence for
inadequate heparinization. Cathet Cardiovasc Diagn 1991;23:141-3.
500. Dougherty KG, Gaos CM, Bush HS,
Leachman DR, Ferguson JJ. Activated clotting times and
activated partial thromboplastin times in patients undergoing
coronary angioplasty who receive bolus doses of heparin.
Cathet Cardiovasc Diagn 1992;26:260-3.
501. Bowers J, Ferguson JJ3. The use
of activated clotting times to monitor heparin therapy
during and after interventional procedures. Clin Cardiol
1994;17:357-361.
502. Ferguson JJ. All ACTs are not
created equal (editorial). Texas Heart Inst J 1992;19:1-3.
503. Bull BS, Korpman RA, Huse WM,
Briggs BD. Heparin therapy during extracorporeal Circulation:
I. problems inherent in existing heparin protocols. J
Thorac Cardiovasc Surg 1975;69:674-84.
504. Young JA, Kisker CT, Doty DB.
Adequate anticoagulation during cardiopulmonary bypass
determined by activated clotting time and the appearance
of fibrin monomer. Ann Thorac Surg 1978;26:231-40.
505. Schiele F, Vuillemenot A, Kramarz
P, et al. Use of recombinant hirudin as antithrombotic
treatment in patients with heparin-induced thrombocytopenia.
Am J Hematol 1995;50:20-5.
506. Brack MJ, More RS, Hubner PJ,
Gershlick AH. The effect of low dose nitroglycerin on
plasma heparin concentrations and activated partial thromboplastin
times. Blood Coagul Fibrinolysis 1993;4:183-6.
507. Habbab MA, Haft JI. Heparin resistance
induced by intravenous nitroglycerin: a word of caution
when both drugs are used concomitantly. Arch Intern Med
1987;147:857-60.
508. Ferguson JJ, Dougherty KG, Gaos
CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural
activated coagulation time and outcome after percutaneous
transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-5.
509. Narins CR, Hillegass WBJ, Nelson
CL, et al. Relation between activated clotting time during
angioplasty and abrupt closure. Circulation 1996;93:667-71.
510. Frierson JH, Dimas AP, Simpfendorfer
CC, Pearce G, Miller M, Franco I. Is aggressive heparinization
necessary for elective PTCA? Cathet Cardiovasc Diagn 1993;28:279-82.
511. Popma JJ, Satler LF, Pichard AD,
et al. Vascular complications after balloon and new device
angioplasty. Circulation 1993;88:1569-78.
512. Koch KT, Piek JJ, de Winter RJ,
et al. Safety of low dose heparin in elective coronary
angioplasty. Heart 1997;77:517-22.
513. Boccara A, Benamer H, Juliard
JM, et al. A randomized trial of a fixed high dose versus
a weight-adjusted low dose of intravenous heparin during
coronary angioplasty. Eur Heart J 1997;18:631-5.
514. Friedman HZ, Cragg DR, Glazier
SM, et al. Randomized prospective evaluation of prolonged
versus abbreviated intravenous heparin therapy after coronary
angioplasty. J Am Coll Cardiol 1994;24:1214-9.
515. Fail PS, Maniet AR, Banka VS.
Subcutaneous heparin in postangioplasty management: comparative
trial with intravenous heparin. Am Heart J 1993;126:1059-67.
516. Kong DF, Califf RM. Post-procedure
heparin: boon or burden? Am Heart J 1998;136:183-5.
517. Garachemani AR, Kaufmann U, Fleisch
M, Meier B. Prolonged heparin after uncomplicated coronary
interventions: a prospective, randomized trial. Am Heart J 1998;136:352-6.
518. Goodman SG, Cohen M, Bigonzi F,
et al. Randomized trial of low molecular weight heparin
(enoxaparin) versus unfractionated heparin for unstable
coronary artery disease: one-year results of the ESSENCE
Study. Efficacy and Safety of Subcutaneous Enoxaparin
in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000;36:693-8.
519. Mandak JS, Blankenship JC, Gardner
LH, et al. Modifiable risk factors for vascular access
site complications in the IMPACT II Trial of angioplasty
with versus without eptifibatide. Integrilin to Minimize
Platelet Aggregation and Coronary Thrombosis. J Am Coll Cardiol 1998;31:1518-24.
520. Aguirre FV, Topol EJ, Ferguson
JJ, et al. Bleeding complications with the chimeric antibody
to platelet glycoprotein IIb/IIIa integrin in patients
undergoing percutaneous coronary intervention. EPIC Investigators.
Circulation 1995;91:2882-90.
521. Blankenship JC, Hellkamp AS, Aguirre
FV, Demko SL, Topol EJ, Califf RM. Vascular access site
complications after percutaneous coronary intervention
with abciximab in the Evaluation of c7E3 for the Prevention
of Ischemic Complications (EPIC) trial. Am J Cardiol 1998;81:36-40.
522. Laarman GJ, Kiemeneij F, van der
Wieken LR, Tijssen JG, Suwarganda JS, Slagboom T. A pilot
study of coronary angioplasty in outpatients. Br Heart
J 1994;72:12-15.
523. Cragg DR, Friedman HA, Almany
SL, et al. Early hospital discharge after percutaneous
transluminal coronary angioplasty. Am J Cardiol 1989;64:1270-4.
524. Johnson LW, Esente P, Giambartolomei
A, et al. Peripheral vascular complications of coronary
angioplasty by the femoral and brachial techniques. Cathet Cardiovasc Diagn 1994;31:165-72.
525. Skillman JJ, Kim D, Baim DS. Vascular
complications of percutaneous femoral cardiac interventions:
incidence and operative repair. Arch Surg 1988;123:1207-12.
526. Khoury M, Batra S, Berg R, Rama
K, Kozul V. Influence of arterial access sites and interventional
procedures on vascular complications after cardiac catheterizations.
Am J Surg 1992;164:205-9.
527. Kresowik TF, Khoury MD, Miller
BV, et al. A prospective study of the incidence and natural
history of femoral vascular complications after percutaneous
transluminal coronary angioplasty. J Vasc Surg 1991;13:328-33;
discussion 333-5.
528. Lumsden AB, Miller JM, Kosinski
AS, et al. A prospective evaluation of surgically treated
groin complications following percutaneous cardiac procedures.
Am Surg 1994;60:132-7.
529. Muller DW, Shamir KJ, Ellis SG,
Topol EJ. Peripheral vascular complications after conventional
and complex percutaneous coronary interventional procedures.
Am J Cardiol 1992;69:63-8.
530. Agrawal SK, Pinheiro L, Roubin
GS, et al. Nonsurgical closure of femoral pseudoaneurysms
complicating cardiac catheterization and percutaneous
transluminal coronary angioplasty. J Am Coll Cardiol 1992;20:610-5.
531. Bogart DB, Bogart MA, Miller JT,
Farrar MW, Barr WK, Montgomery MA. Femoral artery catheterization
complications: a study of 503 consecutive patients. Cathet Cardiovasc Diagn 1995;34:8-13.
532. Kent KC, Moscucci M, Mansour KA,
et al. Retroperitoneal hematoma after cardiac catheterization:
prevalence, risk factors, and optimal management. J Vasc
Surg 1994;20:905-10; discussion 910-3.
533. Feld R, Patton GM, Carabasi RA,
Alexander A, Merton D, Needleman L. Treatment of iatrogenic
femoral artery injuries with ultrasound- guided compression.
J Vasc Surg 1992;16:832-40.
534. Schaub F, Theiss W, Heinz M, Zagel
M, Schomig A. New aspects in ultrasound-guided compression
repair of postcatheterization femoral artery injuries.
Circulation 1994;90:1861-5.
535. Kim D, Orron DE, Skillman JJ,
et al. Role of superficial femoral artery puncture in
the development of pseudoaneurysm and arteriovenous fistula
complicating percutaneous transfemoral cardiac catheterization.
Cathet Cardiovasc Diagn 1992;25:91-7.
536. Sanborn TA, Gibbs HH, Brinker
JA, Knopf WD, Kosinski EJ, Roubin GS. A multicenter randomized
trial comparing a percutaneous collagen hemostasis device
with conventional manual compression after diagnostic
angiography and angioplasty. J Am Coll Cardiol 1993;22:1273-9.
537. Silber S. Hemostasis success rates
and local complications with collagen after femoral access
for cardiac catheterization: analysis of 6007 published
patients. Am Heart J 1998;135:152-6.
538. Kussmaul WG, Buchbinder M, Whitlow
PL, et al. Femoral artery hemostasis using an implantable
device (Angio-Seal) after coronary angioplasty. Cathet Cardiovasc Diagn 1996;37:362-5.
539. Kuntz RE, Piana R, Pomerantz RM,
et al. Changing incidence and management of abrupt closure
following coronary intervention in the new device era.
Cathet Cardiovasc Diagn 1992;27:183-90.
540. Simpfendorfer C, Belardi J, Bellamy
G, Galan K, Franco I, Hollman J. Frequency, management
and follow-up of patients with acute coronary occlusions
after percutaneous transluminal coronary angioplasty.
Am J Cardiol 1987;59:267-9.
541. de Feyter PJ, de Jaegrere PP,
Serruys PW. Incidence, predictors, and management of acute
coronary occlusion after coronary angioplasty. Am Heart J 1994;127:643-51.
542. Klein LW, Kramer BL, Howard E,
Lesch M. Incidence and clinical significance of transient
creatine kinase elevations and the diagnosis of non-Q
wave myocardial infarction associated with coronary angioplasty.
J Am Coll Cardiol 1991;17:621-6.
543. Kong TQ, Davidson CJ, Meyers SN,
Tauke JT, Parker MA, Bonow RO. Prognostic implication
of creatine kinase elevation following elective coronary
artery interventions. JAMA 1997;277:461-6.
544. Myocardial infarction redefined:
a consensus document of The Joint European Society of
Cardiology/American College of Cardiology Committee for
the redefinition of myocardial infarction. J Am Coll Cardiol
2000;36:959-69.
545. Aguilar C, Reza A, Garcia JE,
Rull JA. Biguanide related lactic acidosis: incidence
and risk factors. Arch Med Res 1992;23:19-24.
546. Smith SC Jr, Blair SN, Criqui
MH, et al. Preventing heart attack and death in patients
with coronary disease. Circulation 1995;92:2-4.
547. Yusuf S, Sleight P, Pogue J, Bosch
JDR, Dagenais G. Effects of an angiotensin-converting-enzyme
inhibitor, ramipril, on cardiovascular events in hight-risk
patients. The Heart Outcomes Prevention Evaluation Study
Investigators. N Engl J Med 2000;342:145-53.
548. Pfeffer MA, Braunwald E, Moye
LA, et al. Effect of captopril on mortality and morbidity
in patients with left ventricular dysfunction after myocardial
infarction. Results of the survival and ventricular enlargement
trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
549. Gibbons RJ, Balady GJ, Beasley
JW, et al. ACC/AHA guidelines for exercise testing: executive
summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee
on Exercise Testing). J Am Coll Cardiol 1997;30:260-315.
550. Bengtson JR, Mark DB, Honan MB,
et al. Detection of restenosis after elective percutaneous
transluminal coronary angioplasty using the exercise treadmill
test. Am J Cardiol 1990;65:28-34.
551. Kadel C, Strecker T, Kaltenbach
M, Kober G. Recognition of restenosis: can patients be
defined in whom the exercise-ECG result makes angiographic
restudy unnecessary? Eur Heart J 1989;10 Suppl G:22-6.
552. Schroeder E, Marchandise B, De
Coster P, et al. Detection of restenosis after coronary
angioplasty for single-vessel disease: how reliable are
exercise electrocardiography and scintigraphy in asymptomatic
patients? Eur Heart J 1989;10 Suppl G:18-21.
553. Honan MB, Bengston JR, Pryor DB,
et al. Exercise treadmill testing is a poor predictor
of anatomic restenosis after angioplasty for acute myocardial
infarction. Circulation 1989;80:1585-94.
554. Laarman GJ, Luijten HE, van Zeyl
LG, et al. Assessment of "silent" restenosis
and long-term follow-up after successful angioplasty in
single vessel coronary artery disease: the value of quantitative
exercise electrocardiography and quantitative coronary
angiography. J Am Coll Cardiol 1990;16:578-85.
555. el-Tamimi H, Davies GJ, Hackett
D, Fragasso G, Crea F, Maseri A. Very early prediction
of restenosis after successful coronary angioplasty: anatomic
and functional assessment. J Am Coll Cardiol 1990;15:259-64.
556. Roth A, Miller HI, Keren G, et
al. Detection of restenosis following percutaneous coronary
angioplasty in single-vessel coronary disease: the value
of clinical assessment and exercise tolerance testing.
Cardiology 1994;84:106-13.
557. Desmet W, De Scheerder I, Piessens
J. Limited value of exercise testing in the detection
of silent restenosis after successful coronary angioplasty.
Am Heart J 1995;129:452-9.
558. Vlay SC, Charnilas J, Lawson WE,
Dervan JP. Restenosis after angioplasty: don't rely on
the exercise test. Am Heart J 1989;117:980-6.
559. Pepine CJ, Cohn PF, Deedwania
PC, et al. Effects of treatment on outcome in mildly symptomatic
patients with ischemia during daily life: the Atenolol
Silent Ischemia Study. Circulation 1994;90:762-8.
560. Ritchie JL, Bateman TM, Bonow
RO, et al. Guidelines for clinical use of cardiac radionuclide
imaging: report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic
and Therapeutic Cardiovascular Procedures (Committee on
Radionuclide Imaging), developed in collaboration with
the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995;25:521-47.
561. Hecht HS, Shaw RE, Chin HL, Ryan
C, Stertzer SH, Myler RK. Silent ischemia after coronary
angioplasty: evaluation of restenosis and extent of ischemia
in asymptomatic patients by tomographic thallium-201 exercise
imaging and comparison with symptomatic patients. J Am Coll Cardiol 1991;17:670-7.
562. Cheitlin MD, Alpert JS, Armstrong
WF, et al. ACC/AHA guidelines for the clinical application
of echocardiography: a report of the American College
of Cardiology/American Heart Association Task Force on
Practice Guidelines (Committee on Clinical Application
of Echocardiography). Developed in collaboration with
the American Society of Echocardiography. Circulation
1997;95:1686-1744.
563. Hecht HS, DeBord L, Shaw R, et
al. Usefulness of supine bicycle stress echocardiography
for detection of restenosis after percutaneous transluminal
coronary angioplasty. Am J Cardiol 1993;71:293-6.
564. Fioretti PM, Pozzoli MM, Ilmer
B, et al. Exercise echocardiography versus thallium-201
SPECT for assessing patients before and after PTCA. Eur Heart J 1992;13:213-9.
565. Pirelli S, Danzi GB, Alberti A,
et al. Comparison of usefulness of high-dose dipyridamole
echocardiography and exercise electrocardiography for
detection of asymptomatic restenosis after angioplasty.
Am J Cardiol 1991;67:1335-8.
566. Rozenman Y, Gilon D, Zelingher
J, et al. One-stage coronary angiography and angioplasty.
Am J Cardiol 1995;75:30-3.
567. Adele C, Vaitkus PT, Wells SK,
Zehnacker JB. Cost advantages of an ad hoc angioplasty
strategy. J Am Coll Cardiol 1998;31:321-5.
568. Breisblatt WM, Ruffner RJ, Uretsky
BF, Reddy PS. Same-day angioplasty and diagnostic catheterization:
safe and effective but riskier in unstable angina. Angiology
1991;42:607-13.
569. Clark VL, Dolce J. Unplanned admissions
after outpatient cardiac catheterization. Clin Cardiol
1993;16:823-6.
570. O'Keefe JH Jr, Gernon C, McCallister
BD, Ligon RW, Hartzler GO. Safety and cost effectiveness
of combined coronary angiography and angioplasty. Am Heart J 1991;122:50-4.
571. O'Keefe JH Jr, Reeder GS, Miller
GA, Bailey KR, Holmes DR, Jr. Safety and efficacy of percutaneous
transluminal coronary angioplasty performed at time of
diagnostic catheterization compared with that performed
at other times. Am J Cardiol 1989;63:27-9.
572. Kimmel SE, Berlin JA, Hennessy
S, Strom BL, Krone RJ, Laskey WK. Risk of major complications
from coronary angioplasty performed immediately after
diagnostic coronary angiography: results from the Registry
of the Society for Cardiac Angiography and Interventions.
J Am Coll Cardiol 1997;30:193-200.
573. Alfonso F, Macaya C, Iniguez A,
Zarco P. Repeat coronary angioplasty during the same angiographic
diagnosis of coronary restenosis. Am Heart J 1990;119:237-41.
574. Myler RK, Stertzer SH, Clark DA,
Shaw RE, Fishman-Rosen J, Murphy MC. Coronary angioplasty
at the time of initial cardiac catheterization: "ad
hoc" angioplasty possibilities and challenges. Cathet Cardiovasc Diagn 1986;12:213-4.
575. Barnathan ES, Schwartz JS, Taylor
L, et al. Aspirin and dipyridamole in the prevention of
acute coronary thrombosis complicating coronary angioplasty.
Circulation 1987;76:125-34.
576. Halle AA III, Wilson RF, Massin
EK, et al. Coronary angioplasty in cardiac transplant
patients: results of a multicenter study. Circulation
1992;86:458-62.
577. Heublein B, Pethig K, Maass C,
Wahlers T, Haverich A. Coronary artery stenting in cardiac
allograft vascular disease. Am Heart J 1997;134:930-8.
578. Pande AK, Gosselin G, Rashdan
I, Carrier M, Leung TK, Bonan R. Coronary angioplasty
in the treatment of post-cardiac transplant coronary artery
disease. J Invas Cardiol 1996;8:252-6.
579. Sandhu JS, Uretsky BF, Reddy PS,
et al. Potential limitations of percutaneous transluminal
coronary angioplasty in heart transplant recipients. Am
J Cardiol 1992;69:1234-7.
580. von Scheidt W, Uberfuhr P, Reichart
B, Steinbeck G. The role of PTCA in the management of
focal critical lesions in transplant coronary artery disease.
Transplant Proc 1995;27:1936-8.
581. Swan JW, Norell M, Yacoub M, Mitchell
AG, Ilsley C. Coronary angioplasty in cardiac transplant
recipients. Eur Heart J 1993;14:65-70.
582. Quigley PJ, Hlatky MA, Hinohara
T, et al. Repeat percutaneous transluminal coronary angioplasty
and predictors of recurrent restenosis. Am J Cardiol 1989;63:409-13.
583. Bauters C, Lablanche JM, Leroy
F, Bertrand ME. Treatment of first restenosis by recurrent
angioplasty: immediate results and angiographic follow-up
after 6 months. Arch Mal Coeur Vaiss 1992;85:1515-20.
584. Glazier JJ, Varricchione TR, Ryan
TJ, Ruocco NA, Jacobs AK, Faxon DP. Factors predicting
recurrent restenosis after percutaneous transluminal coronary
balloon angioplasty. Am J Cardiol 1989;63:902-5.
585. Teirstein PS, Hoover CA, Ligon
RW, et al. Repeat coronary angioplasty: efficacy of a
third angioplasty for a second restenosis. J Am Coll Cardiol
1989;13:291-6.
586. Deligonul U, Vandormael M, Kern
MJ, Galan K. Repeat coronary angioplasty for restenosis:
results and predictors of follow-up clinical events. Am Heart J 1989;117:997-1002.
587. Bauters C, Lablanche JM, McFadden
EP, Leroy F, Bertrand ME. Clinical characteristics and
angiographic follow-up of patients undergoing early or
late repeat dilation for a first restenosis. J Am Coll Cardiol 1992;20:845-8.
588. Bauters C, Lablanche JM, Leroy
F, Bertrand ME. Morphological changes of coronary stenosis
after repeated balloon angioplasties: a quantitative angiographic
study. Cathet Cardiovasc Diagn 1991;24:158-60.
589. Henderson RA, Pipilis A, Cooke
R, Timmis AD, Sowton E. Angiographic morphology of recurrent
stenoses after percutaneous transluminal coronary angioplasty:
are lesions longer at restenosis? Int J Card Imaging 1990;6:77-84.
590. Kitazume H, Ichiro K, Iwama T,
Ageishi Y. Repeat coronary angioplasty as the treatment
of choice for restenosis. Am Heart J 1996;132:711-5.
591. Reeder GS, Bresnahan JF, Holmes
DR, Jr., Litvack F. Excimer laser coronary angioplasty:
results in restenosis versus de novo coronary lesions.
Excimer Laser Coronary Angioplasty Investigators. Cathet Cardiovasc Diagn 1992;25:195-9.
592. Erbel R, Haude M, Hopp HW, et
al. Coronary-artery stenting compared with balloon angioplasty
for restenosis after initial balloon angioplasty. Restenosis
Stent Study Group. N Engl J Med 1998;339:1672-8.
593. Mehta VY, Jorgensen MB, Raizner
AE, Wolde-Tsadik G, Mahrer PR, Mansukhani P. Spontaneous
regression of restenosis: an angiographic study. J Am Coll Cardiol 1995;26:696-702.
594. Serruys PW, Emanuelsson H, van
der Giessen W, et al. Heparin-coated Palmaz-Schatz stents
in human coronary arteries: early outcome of the Benestent-II
Pilot Study. Circulation 1996;93:412-22.
595. Dussaillant GR, Mintz GS, Pichard
AD, et al. Small stent size and intimal hyperplasia contribute
to restenosis: a volumetric intravascular ultrasound analysis.
J Am Coll Cardiol 1995;26:720-4.
596. Serruys PW, Kay IP, Disco C, Deshpande
NV, de Feyter PJ. Periprocedural quantitative coronary
angiography after Palmaz-Schatz stent implantation predicts
the restenosis rate at six months: results of a meta-analysis
of the BElgian NEtherlands Stent study (BENESTENT) I,
BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter
Ultrasound Stent In Coronaries. J Am Coll Cardiol 1999;34:1067-74.
597. Ellis SG, Savage M, Fischman D,
et al. Restenosis after placement of Palmaz-Schatz stents
in native coronary arteries: initial results of a multicenter
experience. Circulation 1992;86:1836-44.
598. Kereiakes DJ, Midei M, Hermiller
J, et al. Procedural and late outcomes following MULTI-LINK
DUET coronary stent deployment. Am J Cardiol 1999;84:1385-90.
599. Hoffmann R, Mintz GS, Dussaillant
GR, et al. Patterns and mechanisms of in-stent restenosis:
a serial intravascular ultrasound study. Circulation 1996;94:1247-54.
600. Hoffmann R, Mintz GS, Kent KM,
et al. Serial intravascular ultrasound predictors of restenosis
at the margins of Palmaz-Schatz stents. Am J Cardiol 1997;79:951-3.
601. Mehran R, Mintz GS, Popma JJ,
et al. Mechanisms and results of balloon angioplasty for
the treatment of in-stent restenosis. Am J Cardiol 1996;78:618-22.
602. Baim DS, Levine MJ, Leon MB, Levine
S, Ellis SG, Schatz RA. Management of restenosis within
the Palmaz-Schatz coronary stent (the U.S. multicenter
experience. The U.S. Palmaz-Schatz Stent Investigators.
Am J Cardiol 1993;71:364-6.
603. Macander PJ, Roubin GS, Agrawal
SK, Cannon AD, Dean LS, Baxley WA. Balloon angioplasty
for treatment of in-stent restenosis: feasibility, safety,
and efficacy. Cathet Cardiovasc Diagn 1994;32:125-31.
604. Gordon PC, Gibson CM, Cohen DJ,
Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis
and redilation within coronary stents: quantitative angiographic
assessment. J Am Coll Cardiol 1993;21:1166-74.
605. Reimers B, Moussa I, Akiyama T,
et al. Long-term clinical follow-up after successful repeat
percutaneous intervention for stent restenosis. J Am Coll Cardiol 1997;30:186-92.
606. Mehran R, Dangas G, Abizaid AS,
et al. Angiographic patterns of in-stent restenosis: classification
and implications for long-term outcome. Circulation 1999;100:1872-78.
607. Meyer T, Schmidt T, Buchwald A,
Wiegand V. Stent wire cutting during coronary directional
atherectomy. Clin Cardiol 1993;16:450-2.
608. Strauss BH, Umans VA, van Suylen
RJ, et al. Directional atherectomy for treatment of restenosis
within coronary stents: clinical, angiographic and histologic
results. J Am Coll Cardiol 1992;20:1465-73.
609. Bottner RK, Hardigan KR. High-speed
rotational ablation for in-stent restenosis. Cathet Cardiovasc Diagn 1997;40:144-9.
610. Stone GW. Rotational atherectomy
for treatment of in-stent restenosis: role of intracoronary
ultrasound guidance. Cathet Cardiovasc Diagn 1996;Suppl
3:73-7.
611. Hara K, Ikari Y, Tamura T, Yamaguchi
T. Transluminal extraction atherectomy for restenosis
following Palmaz-Schatz stent implantation. Am J Cardiol
1997;79:801-2.
612. Patel JJ, Meadaa R, Cohen M, Adiraju
R, Kussmaul WG3. Transluminal extraction atherectomy for
aortosaphenous vein graft stent restenosis. Cathet Cardiovasc Diagn 1996;38:320-4.
613. Goods CM, Jain SP, Liu MW, Babu
RB, Roubin GS. Intravascular ultrasound-guided transluminal
extraction atherectomy for restenosis after Gianturco-Roubin
coronary stent implantation. Cathet Cardiovasc Diagn 1996;37:317-9.
614. Virk SJ, Bellamy CM, Perry RA.
Transluminal extraction atherectomy for stent restenosis
in a saphenous vein bypass graft [letter]. Eur Heart J
1997;18:350-1.
615. Ikari Y, Yamaguchi T, Tamura T,
Isshiki T, Saeki F, Hara K. Transluminal extraction atherectomy
and adjunctive balloon angioplasty for restenosis after
Palmaz-Schatz coronary stent implantation. Cathet Cardiovasc Diagn 1993;30:127-30.
616. Chow WH, Chan TF. Pullback atherectomy
for the treatment of intrastent restenosis [letter]. Cathet Cardiovasc Diagn 1997;41:94-5.
617. Cecena FA. Stenting the stent:
alternative strategy for treating in-stent restenosis.
Cathet Cardiovasc Diagn 1996;39:377-82.
618. Debbas N, Stauffer JC, Eeckhout
E, Vogt P, Kappenberger L, Goy JJ. Stenting within a stent:
treatment for repeat in-stent restenosis in a venous graft.
Am Heart J 1997;133:460-3.
619. Moris C, Alfonso F, Lambert JL,
et al. Stenting for coronary dissection after balloon
dilation of in- stent restenosis: stenting a previously
stented site. Am Heart J 1996;131:834-6.
620. Waksman R, Bhargava B, Mintz GS,
et al. Late total occlusion after intracoronary brachytherapy
for patients with in-stent restenosis. J Am Coll Cardiol
2000;36:65-8.
621. Murray CJ, Lopez AD, Jamison DT.
The global burden of disease in 1990: summary results,
sensitivity analysis and future directions. Bull World Health Organ 1994;72:495-509.
622. Cohen DJ, Sukin CA. Cost-effectiveness
of coronary interventions. Heart 1997;78 Suppl 2:7-10.
623. Gold MR, Siegel JE, Russell LB,
Weinstein MC. Gold MR, ed. Cost-Effectiveness in Health
and Medicine. NY: Oxford University Press; 1996.
624. Wong JB, Sonnenberg FA, Salem
DN, Pauker SG. Myocardial revascularization for chronic
stable angina: analysis of the role of percutaneous transluminal
coronary angioplasty based on data available in 1989.
Ann Intern Med 1990;113:852-71.
625. Cohen DJ, Breall JA, Ho KK, et
al. Evaluating the potential cost-effectiveness of stenting
as a treatment for symptomatic single-vessel coronary
disease: use of a decision-analytic model. Circulation
1994;89:1859-74.
626. Cohen DJ, Krumholz HM, Sukin CA,
et al. In-hospital and one-year economic outcomes after
coronary stenting or balloon angioplasty: results from
a randomized clinical trial. Stent Restenosis Study Investigators.
Circulation 1995;92:2480-7.
627. Kuntz KM, Tsevat J, Goldman L,
Weinstein MC. Cost-effectiveness of routine coronary angiography
after acute myocardial infarction. Circulation 1996;94:957-65.
628. Sim I, Gupta M, McDonald K, Bourassa
MG, Hlatky MA. A meta-analysis of randomized trials comparing
coronary artery bypass grafting with percutaneous transluminal
coronary angioplasty in multivessel coronary artery disease.
Am J Cardiol 1995;76:1025-29.
629.
Weintraub WS, Mauldin PD, Becker E, Kosinski AS, King
SB III. A comparison of the costs of and quality of
life after coronary angioplasty or coronary surgery
for multivessel coronary artery disease: results from
the Emory Angioplasty Versus Surgery Trial (EAST). Circulation
1995;92:2831-40.
© 2001 by the American College of Cardiology
and American Heart Association |
